










































Herein,! packaging! 293T! cells! were! genetically! engineered! with! biotin!
mimicking!synthetic!peptides!and!different!cell!membrane!anchoring!strategies!
for! optimal! streptavidin! binding! were! tested.! We! have! identified! a! flanked!







binding.! Accordingly,! addition! of! micromolar! concentrations! of! biotin! to!
captured! LVs! resulted! in! an! overall! yield! of! ≥60%.! Analysis! of! eluted! LVs!
revealed! high! purity! levels,! with! a! ≤3Mlog! and! 2Mlog! reduction! of! DNA!
contamination!and!host!cell!proteins,!respectively.!This!oneMstep!purification!
was! also! tested! for! scalable! vector! processing! using! streptavidin! monolith!
affinity!chromatography!and!preliminary! results!were!encouraging!with!20%!
overall!yield.!
In! conclusion,! we! developed! a! singleMstep! affinity! chromatography! which!
allows! specific! purification! and! concentration! of! infectious! vectors!modified!
with!a!biotin!mimic.!Based!on!intended!usage,!efficient!LV!purification!can!be!
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on! biotinMstreptavidin! system! for! the! manufacturing! for! gene! therapy!
application.!This!thesis!has!the!following!structure:!!
Chapter!1!presents!a!review!of!the!scientific!literature!for!gene!therapy,!with!






















human! gene! transfer! experiment! in! 1989.! This! section! offers! a! brief!
introduction!to!gene!therapy!with!an!emphasis!on!adoptive!T!cell!transfer!by!
(i)! outlining! major! milestones! that! have! defined! the! field,! (ii)! providing! an!






application! to! treat!diseases!(Escors!and!Breckpot,!2010).! In!Europe,!gene!
therapies!are!classified!as!Advanced!Therapy!Medicinal!Products!(ATMPs),!




The! European! Medicine! Agency! (EMA)! defines! a! gene! therapy! medicinal!
product!(GTMP)!as!a!biological!medicinal!product!that:!
•! contains! an! active! substance! which! contains! or! consists! of! a!
recombinant!nucleic!acid!used!in!or!administered!to!humans!to!regulate,!
repair,!replace,!add!or!delete!genetic!sequence!!
•! its! therapeutic,!prophylactic!or!diagnostic!effect! relates!directly! to! the!








•! that! mediate! their! effects! by! transcription! and/or! translation! of!
transferred!genetic!material!and/or!by!integrating!into!the!host!genome!
and! that! are! administered! as! nucleic! acids,! viruses,! or! genetically!
engineered!microMorganisms.!The!products!may!be!used!to!modify!cells!
in! vivo! or! transferred! to! cells! ex! vivo! prior! to! administration! to! the!
recipient.!
!
Gene! therapies’! aim! is! to! treat! known! causes! of! diseases! instead! of! only!













with! severe! combined! immunodeficiency! (SCID)! cause! by! adenosine!
deaminase!(ADA)Mdeficiency!(ADAM!SCID)!were!treated!with!autologous!T!cells!





pioneering! studies,! the! successive! decade! (1989M1999)! witnessed! the!
approval!of!close!to!500!gene!therapy!trials!worldwide,!with!its!highest!peak!of!









and!NIH! instated!new! initiatives! to!provide!greater!protection! for!patients! in!
gene! therapy! trials! (McCarthy,! 2000).! However,! in! the! years! succeeding!
Gelsinger’s! case,! the! field! suffered! a! further! blow! as! several! cases! of!
insertional!mutagenesis!following!γMRV!transduction!were!reported.!A!quarter!
of!patients!with!XMlinked!SCID!that!were! treated!with!autologous!retrovirally!




trials! for! the! treatment! of! WiskottMAldrich! Syndrome! (WAS)! (Galy! and!
Thrasher,! 2011)! and! for! XMlinked! chronic! granulomatous! disease! (XMCGD)!
(Grez! et! al.,! 2011).! It! is! however! interesting! to! note! that! insertional!
mutagenesis! leading! to!oncogenesis!has!only!been! reported! for!genetically!








to! investigate! insertional! mutagenesis! (Montini! et! al.,! 2009)! and! highM
throughput!analysis!of!insertional!sites!(Schmidt!et!al.,!2007).!
1.1.2* Current*status*of*gene*therapy*trials**
As!of!April!2017,!a! total!of!2463!clinical! trials! related! to!gene! therapy!have!
been! completed,! onMgoing! or! approved! worldwide! since! 1989,! using! the!
searchable! database! that! is! periodically! updated! on!The# Journal# of# Gene#




(http://www.wiley.com/legacy/wileychi/genmed/clinical/).! The! majority! of!




2012),! around! 65%! of! worldwide! gene! therapy! trials! are! targeting! cancer!
diseases! with! several! strategies! being! used,! most! notably! antiMtumour!




Table*1.1:* Indications*of*gene* therapy*clinical* trials* from*1989* to*April*2017.*




cytokines! (15.2%),! receptors! (10.5%)! and! gene! deficiency! replacement!
(8.4%).!Different! types!of! vector! types!are! employed! to! deliver! the! genetic!
material!to!target!cells!(Table!1.2)!with!modified!viruses,!termed!viral!vectors,!
used!in!67.7%!of!gene!therapy!trials.!Although!nonMviral!method!were!first!used!























most! commonly! utilised,! however! due! to! the! Gelsinger! case! and! the!
occurrences!of!insertional!mutagenesis,!the!field!has!drifted!away!from!these!





2012,! the! values! of! the! formers! had! decreased! to! 23.3%! and! 19.7%,!
respectively,!while! the!use!of!AAVs!and!LVs! increased! to! 4.9%!and!2.9%,!
respectively,!in!trials!worldwide!(Ginn!et!al.,!2013).!Following!suit,!as!of!April!
2017,!AVs!and!RVs!have!further!decreased!to!21.2%!and!18.3%,!respectively,!






































witnessed! in!earlier!studies,! these!percentages! to!reach!registration!are!not!
unexpectedf! and! as! haematologist! and! president! of! Spark! Therapeutics!
Katherine!High!mentioned!“there!were!serious!questions!about!whether!gene!
therapy! would! ever! make! it”! (Bender,! 2016).! Nonetheless,! several! gene!
therapy!trials!prevailed,!mostly!from!smallMscale!academic!studies,!that!“have!
the! ability! to! powerfully! reorient! the! field”! says!High.! These! small! steps! in!
studies!proving!efficacy!of!gene!therapy!have!witness!the!boom!of!dozens!of!
gene!therapy!startMups!(Bender,!2016).!To!date,!four!gene!therapy!products!









and! FDA! approved! the! oncolytic! virus! Imlygic! (BioVex)! a!modified! form! of!
herpes!simplex!virus!1!to!treat!melanoma!lesions!(Rehman!et!al.,!2016).!And!
finally,!in!2016,!the!EMA!approved!Strimvelis!(GlaxoSmithKline)!as!the!first!RV!
ex# vivo! stem! cell! gene! therapy! for! the! treatment! of! paediatric! ADAMSCID!
(Schimmer! and! Breazzano,! 2016).! As! gene! therapies! are! approaching!
regulatory!approval!for!marketing!authorisation,!several!challenges!to!translate!
these!therapies!into!commercial!products!are!emerging!as!“it!is!only!in!the!last!




quality,! robustness,! safety! and! risk! benefit! at! the! levels! necessary! to! gain!
regulatory!approval”!said!Christian!Meyer,!chief!medical!officer!at!UniQure.!!
1.1.3* Future*challenges**




industry.! For! examples,! to! reduce! the! risk! of! insertional!mutagenesis,! selfM
inactivating! (SIN)! viral! vectors! have! been! developed! in! which! all! promoter!
elements!and!enhancers!have!been!deleted!from!the!U3!region!of! the! long!
terminal! repeat! (LTR)! (Modlich!et!al.,!2006).!The! first!approval!by! the!EMA!
granted! to! a! gene! therapy!product,!Glybera,! has! opened! the!door! to! other!
products!seeking!to!gene!therapy!registration.!With!the!advancement!of!gene!
therapies! and! their! promising! early! results,! for! example! of! adoptive! T! cell!




field! is! witnessing! the! current! maturation! of! viral! vector! manufacturing! for!
scalable! application! (Sheridan,! 2011f! Dolgin,! 2012f! Segura! et! al.,! 2013f!
Merten!et!al.,!2016).!!
For! the! commercialization! of! gene! therapy! vector! products,! two! major!
obstacles! are! recognized! (i)! in! the! upstream! process! which! is! the! lack! of!
scalable! bioprocessing! that! is! compliant! with!Good!Manufacturing! Practice!
(GMP)!standards!and!(ii)!in!the!downstream!process!of!vector!purification!and!
final! formulation!of! the!product! (Denèfle,!2011).!Fulvio!Mavilio! the!scientific!
director!of!Généthon!(nonprofit,!France)!described!the!vector!processing!as!
“primitive”!and!added!“we’re!not! talking!about! robust!processes! that!can!be!







and! LVs! (Schweizer! and!Merten,! 2010).! Adherent! cell! based! systems! are!
difficult!to!scale!up!according!to!many!experts!in!the!field,!as!it!requires!the!
addition!of!extra!cell!culturing!vessel!(for!scaleMup)!which!is!not!feasible!as!it!







which! will! be! thoroughly! discussed! in! later! section! 1.3.4.! These! present! a!
significant!concern!as!they!can!cause!unwanted!immune!responses!in!product!
recipient! patients! and! thus! the! refinement! of! final! vector! product! is! a!
prerequisite! in! terms!of!gene!therapy!safety.!Therefore,! the!development!of!
commerciallyMviable,! robust! and! scalable! manufacturing! routes! is! an! area!
requiring!significant!attention!for!gene!therapy!products.!!
1.2* Lentiviral*vector*for*gene*therapy*
In! the! previous! section,! a! broad! introduction! to! gene! therapy! has! been!




The! shift! towards! these! vectors! was! mainly! driven! by! several! key!
characteristics! and! factors! allowing! them! to! become! of! increasing! interest,!
such!as!their!ability!to!transduce!nonMdividing!cells!as!well!as!appear!to!have!
a! safer! insertion! profile! (Naldini! et! al.,! 1996f!Sheridan,! 2011).! The!general!







Lentiviruses! (LVs)! are! classified! as! disease! causing! pathogens! that! are!
characterized!by! a! long! incubation! period,! persistent! and! affecting!multiple!
organs!proving!invariably!fatality!(Haase,!1986f!Clements!and!Zink,!1996).!LVs!
belong! to! a! subfamily! within! the! Retroviridae! family! of! viruses,! called!









immunodeficiency! virus! (SIV)! and!bovine! immunodeficiency! virus! (BIV)! are!
being! explored! for! safer! and! efficient! gene! transfer! vectors! (Binder! and!
Dropulic,! 2008).# LVs! consist! of! singleMstranded! (ssRNA)! genome! of! 7M11!
kilobases,!of!which!two!copies!homodimerise!and!are!packaged!in!enveloped!
viral! particles! surrounded! by! host! lipid! bilayer.! Particles! are! slightly!
pleomorphic! and! spherical! measuring! ~80M120! nm! in! diameter! (Vogt! and!
Simon,!1999).!A!typical!LV!particle!is!depicted!in!Figure!1.1a!with!its!main!viral!
components.!In!LV!native!form,!the!two!copies!of!RNA!genome!are!bound!to!
nucleocapsid! (NC)!proteins.!This!complex! is!enclosed!within!a!capsid! (CA)!
along!with!viral!proteins!required!for!LV!life!cycle!(PR,!proteasef!RT,!reverse!
transcriptasef! and! IN,! integrase).! A! layer! consisting! of! the! host! cell! lipid!

















(repeated)! regions! which! contains! transcriptions! signals! used! in! integrated!
proviral!DNA.!Following!the!R!sequence!at!the!5’!end!of!the!genome!is!(i)!a!U5!
nonMcoding!cisMacting!regulatory!sequence!(ii)!a!primer!binding!site!(PBS)!for!
cellular! tRNA! binding! initiating! reverse! transcription,! and! (iii)! a! leader!
sequence! that! encompasses! the! genome! packaging! signal! (ψ)! as! well! as!
splice!donor!signals!that!are!crucial!for!the!generation!of!spliced!mRNAs.!The!
3’!end!of!the!genome!contains!a!polypurine!tract!that!is!fundamental!for!the!








enabling! host! cell! manipulation! for! viral! production,! provirus! entry! and!
integration!into!host!cell!genome!(Lever!et!al.,!2004).!Two!regulatory!genes!tat#
and! rev! are! involved! on! transcriptional! and! posttranscriptional! levels,!
respectively! (Farson! et! al.,! 2001).! Tat! protein! promotes! the! transcriptional!
elongation!by!binding!to!the!transactivation!response!(TAR)!element!in!the!U3!













shown! to! play! an!essential! role! in! viral! replication! both! in# vivo#and! in# vitro#
(Zhang! et! al.,! 2000).! And! finally,! the! HIVM1! specific! protein! Vpu! has! been!
demonstrated! to! both! sequester! and! degrade! CD4! molecules! in! the!































transcription! commences! by! core! rearrangement! for! the! formation! of! the!
reverse!transcription!complex!(RTC).!Due!to!the!complex!nature!of!LVs,!HIVM
1!RTC! has! been! shown! to! contain!more! protein! than! that! of!Molony!MLV!
(MoMLV)! RTC,! with! not! only! viral! RNA,! RT,! IN,! CA,! but! also! with! a!
phosphorylated!MA!and!Vpr!(Hu!and!Hughes,!2012).!The!reverse!transcription!









3’!end!of! the!RNA!genome!and!hybridising! to! its!R!sequence.!This!priming!
‘hop’! allows! the! synthesis! of! (M)ssDNA! to! the! 5’! end! of! the! viral! genome.!
Simultaneously,!RNase!H!degrades!the!template!RNA!with!the!exception!of!
RNase!digestion!resistant!regions,!namely!the!3’!polypurine!tract!(PPT)!and!
the!central!PPT!(cPPT),!which! in! turn!act!as!primers! for! the!positive!strand!
synthesis.!This! process!proceeds! from! the!3’!PPT! to! the! end!of! the! tRNA,!
whereby! the! synthesis! is! terminated! upon! RT! encountering! a! methylated!
nucleotide!in!the!primer.!This!complex!process!generates!an!area!of!homology!
at!the!PBS!between!the!(+)!and!(M)!ssDNA,!allowing!subsequent!second!strand!

















Hope,! 2015).! Precise! sequences! of! events! are! not! yet! fully! elucidated,!
however!uncoating!is!known!to!be!accompanied!with!the!transition!between!
RTC! into! the! preMintegration! complex! (PIC)f! as! successful! reverse!
transcription!has!been!shown!to!take!place!in!the!protected!milieu!provided!by!
the! capsid! cone! (Arhel! et! al.,! 2007f! Jacques! et! al.,! 2016).! Interestingly,!
inhibition!of!RT!has!been!shown!to!delay!uncoating!suggesting!that!the!former!
occurs! later! than! the! initiation!of! reverse! transcription! (Hulme!et!al.,!2011).!
Although!the!extent!of!uncoating!before!the!nuclear!translocation!of!the!RTC!
is!not!yet!clear,! the!PIC!composed!of!proviral!DNA,!MA,!IN!and!Vpr!enable!
nuclear! import! without! the! requirement! of! nuclear!membrane! breakage! for!
chromatin! access! in! nonMdividing! cells! (Ambrose! and! Aiken,! 2014).! The!
molecular! mechanism! governing! nuclear! entry! of! PIC! is! not! yet! fully!
understood,!however! the!presence!of!nuclear! localisation!signals! in!all!PIC!



















phosphodiester!bonds!via! the!3’hydroxyle!groups,!proviral!DNA! is! joined! to!
target!DNA.!Due!to!the!integration!site!separation!of!5!base!pairs!for!both!target!
DNA!strands,!repair!of!this!integration!results!in!a!direct!duplication!of!the!five!
base!pairs!which! then!flank! the! integrated!proviral!DNA.!Accordingly,! in!the!
final!strep!of!integration,!the!unpaired!dinucleotide!of!the!5’ends!of!the!proviral!
DNA!are!cleaved!and! the! five!base!pair! residues!on!both!ends!of! the!viral!
genome!are!repaired!and!ligated!to!target!DNA,!resulting!in!repeated!residues!
flanking!the!provirus!(Craigie,!2001).!HIV!integration!does!not!appear!to!have!












of! the! first! proteins! to! be! translated.! Tat! proteins,! owing! to! its! name,! then!
stimulates!transcription!initiations!and!elongation!of!RNA!genome!in!a!positive!
feedback! loop!by!binding!to! the! transMactivating!response!region!(TAR)!and!




Cdk9! and! Cyclin! T,! thus! increasing! transcriptional! efficiency! by! 100Mfold!
(Romano!et!al.,!1999f!Kim!et!al.,!2002f!SchulzeMGahmen!et!al.,!2014).!The!
binding!of!Rev!to!Rev!response!element!(RRE)!in!both!singly!and!unspliced!
transcripts! significantly! enhances! their! nuclear! export! as!well! as! increases!
their!stabilisation!(Pollard!and!Malim,!1998).!!
Translation##
Singly! spliced! transcripts! serve! for! the! production! of! the! remaining! nonM
structural!proteins!along!with! the!envelope!glycoproteinf!while! the!unspliced!
transcript!serving!as!either!template!for!structural!proteins!translation!(Gag!and!
GagMPol)! or! remaining! unspliced! transcript! for! virion! packaging.! The!main!
structural!proteins!Gag!is!translated!as!precursor!polyprotein!containing!MA,!




encapsidation! of! the! viral! genome! by! NC! binding! to! the! packaging! signal,!
present! only! on! the! unspliced! mRNA.! Simulationsly,! the! translation! of! the!
envelope! precursor! glycoprotein,! gp120! and! gp41! for! HIVM1,! leads! to! its!
trafficking! through! the! secretory! pathway! from! the! rough! endoplasmic!
reticulum! through! the!Golgi!apparatus! routing! to! the! plasma!membrane! for!
virion!recruitment!(Checkley!et!al.,!2011).!#
Assembly#and#Budding##
The! assembly! of! viral! components! leading! to! a! membrane! fission! for! the!
release!of! virions! is!mediated!by! the! cellular! endosomal! sorting! complexes!
required! for! the! transport! (ESCRT)! pathway! (reviewed! in! (Votteler! and!
Sundquist,!2013)).!Upon!Gag!multimerisation,!factors!in!the!ESCRT!pathway!
are!recruited,!with!ESCRTMIII!driving!membrane!scission!at!the!virus!budding!
site! resulting! in! virion! release! from!host! cell! surface! as! immature! particles!





This! proteolytic! processing! of! particles! results! in! dramatic! protein!






to!stably! integrate! into! target!cell!genome,!allowing! long! term!expression!of!















transduction! of! rat! neurons! using! an! HIVM1! derived! vector! system! that!
contained!all!HIVM1!genome!proteins.!This!landmark!study!represented!the!1st!





















recombination! events! leading! to! replication! competent! lentivirus! (RCL).!
However! further! improvements! were! required! and! since! then! several! LV!
generations! have! been! developed! (mostly! based! on! HIVM1)! (Binder! and!
Dropulic,!2008).!Biosafety!was! increased!with! the!2nd!generation!system! in!
which!the!accessory!proteins!vif,!vpr,!vpu!and!nef!were!removed!(Zufferey!et!
al.,!1997).!To!further!increase!biosafety,!3rd!generation!packaging!system!was!
developed! in! which! tat! gene! was! removed! and! a! constitutive! promoter!












Modlich!et!al.,!2006).!Finally,! the! inclusion!of! the!woodchuck!hepatitis!virus!
posttranscriptional! regulatory! element! (WPRE)! in! the! transfer! vector! was!
shown!to!significantly!enhance!transgene!expression!(Zufferey!et!al.,!1999),!
which! was! a! critical! progress! that! aided! the! advance! of! LVs! to! clinical!
application.!In!addition,!further!safety!improvements!were!accomplished!by!the!
removal! of! residual! sequence! homology! between! transfer! vector! and!
packaging!plasmid!due!to!the!presence!of!the!packaging!signal!(Ψ)!which!is!




using! the! 3rd! generation! packaging! system! with! codon! optimized! gag8pol!
further! reduces! the! frequency! of! potential! recombination! events! and! thus!
improves!the!safety!profile!of!LVs!(Tareen!et!al.,!2013).!!
The!first!LVMbased!clinical!trial!was!initiated!in!2003!for!the!treatment!of!chronic!


























I" I/II* II* II/III* III* Total*
Cancer*diseases* " " " " " 83*
B"cell"malignancies*"" 23" 11" 10" " " "
Melanoma" 4" " " " " "
Multiple"Myeloma"" 3" " 1" " " "
Neural"cancers*"adult/pediatric"" 7" " " " " "
Sarcomas"" 1" " 2" " " "
Lung"squamous"cell"carcinoma" 1" 1" " " " "
Hepatocellular"carcinoma" 2" 2" " " " "
Ovarian"cancer"" 2" " " " " "
Metastatic"Expressing"NYGESOG1" 4" " " " " "
Mesothelin"Expressing"Cancer" 1" " " " " "
Metastatic"Pancreatic" 1* * * * * *
Monogenic*diseases* " * * * * 45*
Sickle"Cell"anemia"and"betaGthalassemia"" 6" 4" * * 3* *
XGlinked"chronic"granulomatous"disease" " 6" 1* * * *
Wiskott"Aldrich"syndrome" 2" 4" * * * *
Fanconi"Anemia" 2" 1" 2* * * *
Childhood"cerebral"adrenoleukodystrophy" " " * 2* 1* *
XGLinked"Severe"Combined"Immune"Deficiency" 2" " * * * *
ADA"deficiency" " 2" * * * *
Fabry"disease" 1" " * * * *
Hemophilia"A" 1" " * * * *
Hungtinton's"disease" 1" " * * * *
Mucopolysaccharidosis"Type"VII"" 1" " * * * *
Netherton"syndrome" 1" " * * * *
Recessive"Dystrophic"Epidermolysis"Bullosa" " 1" * * * *
XGlinked"ALD" " 1" * * * *
Hungtinton's"disease" 1" " * * * *
Neurological*disorders* " " * * * 5*
Metachromatic"Leukodystrophy"and"
adrenoleukodystrophy" " 2" * * *
*
Parkinson's"Disease"" " 2" * * * *
Amyotrophic"Lateral"Sclerosis" " 1" * * * *
Ocular*diseases* " " * * * 4*
AgeGrelated"Macular"Degeneration"" 1" " * * * *
Retinitis"Pigmentosa"Associated"with"Usher"
Syndrome"Type"1B" " 2" * * *
*
Stargardt's"Macular"Degeneration"" " 2" * * * *
Infectious*disease* " " * * * 20*
HIV"infection" 10" 8" 1* * * *
Cadriovascular*disease" " " " * * 1*







in! trials! for! the! treatment!of!cancer!disease!(n=83)!compared!to!monogenic!
disorders! (n=45)! (Table! 1.3).!This! can!be!explained!by! the! increase! in! the!
development!in!gene!therapies!such!as!hematopoietic!stem!cell!gene!therapy!
and! antiMtumour! immunotherapy.! Moreover,! immunotherapy! is! currently!
recognized! as! a! fourth! pillar! of! cancer! treatments! alongside,! surgery,!
chemotherapy!and! radiotherapyf!by!harnessing! the! intrinsic!mechanisms!of!
the!immune!system!to!actively!recognize!and!destroy!tumours.!As!this!is!our!
laboratory’s! field! of! study,! a! brief! overview! of! one! of! its! main! modalities,!
adoptive! T! cell! therapy! (ACT)! will! be! discussed,! in! which! tumourMspecific!
cytotoxic! T! cells! are! infused! back! into! a! patient! with! the! aim! to! hunt! and!
eradicate! tumour! cells.! There! are! numerous! benefits! of! ACT! compared! to!
conventional! treatments,! as! T! cell! responses:! (i)! are! specific,! so! can!
distinguish! between! cancerous! and! healthy! cellsf! (ii)! can! traffic! to! antigen!
expressing! site! thus! tackling! the! challenge! of! metastasisf! and! finally! (iii)!
maintain! therapeutic! activity! against! specific! antigen! years! after! initial!




from! resected!metastatic!melanoma! lesions! and! infused! back! into! patients!
(Rosenberg!et!al.,!1994).!Even!though!results!were!encouraging,!with!a!recent!
analysis!indicating!overall!and!complete!response!rates!were!almost!50%!and!
20%!respectively!(Rosenberg!et!al.,!2011)f!TIL! therapy!has!been! limited! to!
metastatic!melanoma.!The!broad!application!of!T!cell!antiMtumour!efficacy!can!
then! be! achieved! by! administration! of! T! cells! that! have! been! genetically!




of! TCR! limits! this! strategy! to! intracellular! antigens! presented! on! major!






cells.!Now! in! their! third!generation,!CARs!are!hybrid! receptors! that!engage!
with! their! antigen! typically! through! an! extracellular! single! chain! variable!
fragment!(scFv).!This!is!fused!to!an!intracellular!CD3Mderived!ITAM!signaling!
chain! and! coMstimulatory! signaling! modules! of! CD28! and! 41BB! or! OX40!
(Cartellieri!et!al.,!2010f!Eshhar!et!al.,!2014).!The!architecture!of!CARs!currently!
used! in!clinical! trials!varies!as!no!optimal!structure!has!been!proven.!Most!
studies! however! use! the! hinge! and! transmembrane! domains! of! CD8α! or!









lymphocytic! leukaemia)! with! retrovirally! transduced! antiMCD19MCAR! T! cells!
reported! very! promising! results! with! complete! remission! and! response!
(Brentjens!et!al.,!2013f!Kochenderfer!et!al.,!2012,!2010).!These!encouraging!
results!led!to!a!surge!of!early!phases!clinical!trials!using!lentiviral!vectors!for!














This! section! discusses! current! and! upcoming! lentiviral! manufacturing!
approaches.! The! current! bottleneck! in! LVMderived! therapies! are:! (i)! lack! of!
scalable! vector! production! in! their! upstream! processing,! (ii)! elimination! of!
process!and!productMderived!impurities!in!vector!downstream!processes,!(iii)!















and!a! labile!disulphide!bond.!After! viral! particle! assembly! and!budding,! for!
certain!viral!envelopes,!such!as!MLVMA!and!RD114!variants,!their!cytoplasmic!
tail!of!TM!proteins!are!processed!by!the!viral!protease!at!a!site!termed!the!R!











2000)! and! stimulation! of! an! innate! immune! response! upon! systemic!
administration!(Pichlmair!et!al.,!2007).!Moreover,!due!to!its!fusogenicity,!stable!
VSVMg!expression!induces!host!toxicity!thus!preventing!its!use!in!stable!and!
continuous! LVMproducing! cells! (Ikeda! et! al.,! 2003).! Several! other! γMRV!
envelope! proteins! have! been! used! to! pseudotype! LVs! such! as! the!




neutral!amino!acid! transporter! is!widely!expressed!on!many!human! tissues!
including!HSCs! (Tailor! et! al.,! 1999f! Rasko!et! al.,! 1999f! Kelly! et! al.,! 2000f!
Goerner! et! al.,! 2001f! Hanawa! et! al.,! 2002f!Green! et! al.,! 2004).!Given! the!
limitations!of!VSVMg,!RD114!represents!an!attractive!alternate!envelope!due!





terminal! residues! such! as! replacement! of! its! cytoplasmic! tail! with! the!













highlighted! being! the! R! cleavage! peptide! site! on! glycoprotein’s! endodomian.! (b)!
RDpro!encodes!precursor!protein!gp160!protein,!which!gets!processed!by!furin!(RMXM
R/KMR)!proteolytic!cleavage! (blue!site)! into!a! receptor!binding!domain!surface!unit!
gp70SU!(361aa)!and!a!transmembrane!unit!p15ETM!(203aa)!that!are!nonMcovalently!




As!mentioned! previously,! the! clinical! application! of! LVs! for! gene! therapies!
requires! the! production! of! high! viral! titre! preparations.! One! of! the! main!
challenges! for!high!overall! yield! is! the!degree!of!complexity!of! this!class!of!
biology.! To! fully! elucidate! the! ongoing! limitations! of! LV! manufacturing!









Recombinant!RVs!are! composed!of! 2%!RNA,! 36%! lipid! and!62%!proteins!
(Andreadis!et!al.,!1999).!Thus,! the! lipid!bilayer!of!viruses,! the!outer!shell!of!







temperature! with! up! to! 8! days! reported! at! 4°C! (Higashikawa! and! Chang,!




as! variations! in! the! envelope! proteins! used! to! pseudotype! lentiviral! vector!
cores!can!determine!vectors’!stability,!titres!and!target!tropism!(Naldini!et!al.,!
1996f!Sakuma!et! al.,! 2010).!As! viral! envelope!proteins! are! responsible! for!
target!binding!and!subsequent!viral! fusion,! the!weakness!of! its! interactions!
depict!vector!instability!and!in!turn!can!cause!vector!inactivation.!In!addition,!
functional!activity!of!viral!vectors!have!been!shown!to!be!negatively!impacted!
by! the! number! of! freezeMthaw! cycles! (Burns! et! al.,! 1993),! which! also! is!
determined! by! pseudotyping! envelope’s! rigidity! to! temperature! alterations.!
Moreover,!pH!of!both!culturing!conditions!and!viral!resuspension!medium!has!
been! regarded! as! an! important! factor! affecting! stability.! Studies! have!
demonstrated!the!effects!of!pH!on!particles!activity!with!the!highest!stability!
attained!at!pH!7.0!at!37°C,!which!significantly!dropped!in!less!than!10!minutes!
at! pH! 6! or! 8! (Higashikawa! and! Chang,! 2001).! However,! a! recent! study!
demonstrated!enhanced!particle!production!and!stability!at!pH!6.0!at!37°C,!
suggesting!that!a!mildly!acidic!pH!may!positively!impact!vector!stability!(Holic!
et! al.,! 2014).! Therefore,! within! a! narrow!window! of! pH! alterations,! particle!
stability!may!be!maintained!or!even!enhanced.!Thus!pHMdependent!particle!
effects!seem! to!be!correlated!with!effects!on!envelope!glycoproteins,!as!at!
extreme! pH! (<5.5! and! >8)! viral! envelope! degradation! resulted! in! fast! and!




culture! medium! osmolality! was! shown! to! also! impact! vector! stability.! The!
addition!of!high!concentration!of!fructose,!a!slow!metabolised!sugar!resulting!
in! low! levels! of! lactate! production,! has! been! described! to! improve! vector!
stability! (Merten,! 2004).! Moreover,! an! increase! in! osmotic! pressure! during!
vector! production! has! been! reported! to! enhance! the! stability! of! infectious!









vector! inactivation! leading! to! reduced!overall! yield.!Additionally,! a! common!





al.,! 2001).! And! finally,! it! is! important! to! note! that! shear! forces! applied! on!
vectors!during!centrifugation!at!high!speed!also!majorly!influences!the!stability!
of!vectors!and!was!recently! reported! to!be!a! function!of! the! type!of! internal!
viral!core!(Kim!and!Lim,!2017),!as!well!as!the!established!notion!of!mechanical!
stability!of!envelope!protein!(Burns!et!al.,!1993).!Therefore,!both!physical!and!













Scalable! bioprocesses! for! LV! production! are! still! in! their! early! stages! of!










produce!viral! titre!4! to!10! fold!higher! than!that!produced!with!HEK293!cells!
(Ausubel!et!al.,!2012f!Merten!et!al.,!2011).!Although!only!slight!changes!have!
been!made!since!its!first!application!in!1990s,!transient!transfection!production!
of! LVs! is! a! simple,! fast! and! flexible! method! that! produces! high! clinically!
relevant!viral!titres.!In!addition,!this!approach!allows!the!use!of!cytotoxic!vector!
components! and! transgenes.! Accordingly,! current! GMPMcompliant! vector!
productions!are!based!on!transient!transfection!of!HEK293Mderived!cells.!As!
mentioned!earlier,!LVs!are!currently!predominantly!used!by!early!phase!clinical!
trials.! These! studies! require! a! relatively! small! number! of! LVs!and! thus! far,!
vector! production! by! transient! transfection! has! proved! adequate.! Current!
largeMscale! productions! can! be! regarded! as! direct! scaleMup! of! smallMscale!
researchMgrade!vector!production!i.e.!scaleMoutf!whereby!the!culturing!surface!
area!is!increased.!This!can!be!achieved!by!the!use!of!vessels!with!increased!
culturing! surface! area! such! as! Corning’s! HYPERflasks®! which! has! been!
evaluated! for!LV!production!generating!clinically! relevant! titres!of!107!–!108!
IU/mL!(Kutner!et!al.,!2009f!Cooper!et!al.,!2011).!To!date,! the!only!culturing!
system!reported!to!have!been!used!in!all!clinical!trials!employing!LVs!is!the!











presented! in! Table! 1.4.! According! to! the! number! of! CFM10! devices! (12M24!
devices)! and! the! number! of! harvests! from! each,! which! is! performed! by! a!
simple!media!exchange,!final!harvest!volumes!range!between!20!and!52!liters!
from!a!single!production!run!(Slepushkin!et!al.,!2003f!Negré,!2008f!Merten!et!
al.,! 2011).!Larger! volumes!of!more! than!100!L! of! viral! supernatant! can!be!
produced! by! employment! of!multiMproduction! protocols! over! several! weeks!
(Ausubel! et! al.,! 2012).! However,! although! such! processes! can! result! in!






CO)! for! transient! LV! production! resulting! in! an! increased! vector! yield!
equivalent!to!three!CFM10!layer!stacks!(Sheu!et!al.,!2015).!To!date,!alternative!
culturing!vessels!that!can!produce!largeMscale!vector!volumes!from!adherent!
















































































differences! in! these! reported!studies,!such!as! type!of!vector!and!analytical!





















suspension! cells! holds! promising! productivity! with! adequate! economics.!









the! while! (iii)! retaining! reproducibility! thus! suffering! from! batchMtoMbatch!
variability!due!to!variation! in! transfection!efficiency!and!plasmid!expression,!
and!(iv)!results! in!significant!quantities!of!naked!DNA!contaminations! in! the!
viral!supernatant!(Ansorge!et!al.,!2010f!Cockrell!and!Kafri,!2007f!Schweizer!
and!Merten,!2010f!Segura!et!al.,!2013f!Stewart!et!al.,!2009).!To!overcome!




components! without! transfer! vector)! and! producing! (containing! all! viral!
components!as!well!as!transfer!vector)!cell! lines!would!provide!the!required!





2002)! and! the! most! commonly! used! envelope! VSVMg,! causing! syncytium!
formation!in!expressing!cells!(Ory!et!al.,!1996f!Yee!et!al.,!1994).!Nonetheless,!
several! groups! have! published! the! generation! of! LV! stable! packaging! and!
producing!cell! lines!and!detailed! information!are!presented! in!Table!1.5.!To!
overcome!VSVMg’s!cytotoxicity,!different!expression!regulatory!methods!were!
used,!with! tetracycline! induction!being! the!most!common,!with! induction!by!
addition!(TetMON)!or! removal!(TetMOFF)!of!doxycycline!(Farson!et!al.,!2001f!
Kafri!et!al.,!1999f!Klages!et!al.,!2000f!Nie!et!al.,!2002f!Throm!et!al.,!2009f!Xu!
et! al.,! 2001).! NonMinducible! vector! producing! cell! lines! have! also! been!
developed! using! alternative! envelopes! such! RDpro! and! another! RD114!
chimera,! RD114MTR! (Di! Nunzio! et! al.,! 2007)! that! was! also! developed! to!






vector! production! is! the! method! of! LV! plasmids! integration! into!
packaging/producing!cell!lines.!The!most!common!integration!method!used!is!
transient!transfection!of!LV!packaging!plasmids!with!antibiotics!selection.!One!
of! its!major! drawback!however! is! attenuation! of! expression!as! it! has! been!
shown! to! eventually! result! in! gene! silencing! and! expression! loss! (Bestor,!
2000).!Moreover,!the!use!of!antibiotics!in!LV!production!for!human!clinical!trials!
is!highly!undesirable!as!they!need!to!be!removed!from!final!product!and!require!
filtration! through! 0.2M0.22μm! as! a! final! step,! which! has! been! shown! to!
decrease! viral! titre! (Ausubel! et! al.,! 2012).!Alternative! strategies! have!been!

















Vector Titre (IU/mL) Reference 
HeLa Plasmid transfections. Clonal selection using antibiotics. Tet-OFF HIV-1 Env HIV-1 7.0E+03 PACK (Yu et al., 1996) 
HeLa Tet-OFF HIV-1 Env HIV-1 3.5E+04 PACK (Kaul et al., 1998) 
HEK293 Tet-OFF VSV-g HIV-1 3.0E+06 PROD (Kafri et al., 1999; Xu et al., 2001) 
HEK293 Tet-OFF VSV-g HIV-1 5.0E+06 PROD (Klages et al., 2000) 
HEK293 Tet-OFF VSV-g HIV-1 5.1E+05 PACK (Farson et al., 2001) 
6.6E+06 PROD 
HEK293T Ecdysone-ON VSV-g HIV-1 1.2E+05 PROD (Pacchia et al., 2001) 
HEK293 Ecdysone-ON VSV-g HIV-1 3.0E+05 PACK (Sparacio et al., 2001) 
HEK293T MLV transduction of HIV Gagpol followed by plasmids 
transfection. Antibiotics selection used. 
N/A RDpro HIV-1 1.4E+07 PACK (Ikeda et al., 2003) 
HEK293 Transfection. Clonal selection using antibiotics. Ecdysone-ON VSV-g SIV 2.6E+05 PACK (Kuate et al., 2002) 
2.4E+05 PROD 
HEK293 Concatemer array technique (co-transfection of linearized 
plasmids). 
Tet-OFF VSV-g HIV-1 3.5E+07 PACK (Ni et al., 2005) 
HEK293  
Transfection. Clonal selection using antibiotics. 
 
Tet-OFF VSV-g HIV-1 2.4E+06 PACK (Cockrell et al., 2006) 
1.0E+07 PROD 
HEK293T Tet-OFF VSV-g HIV-1 5.0E+07 PACK (Throm et al., 2009) 
HEK293 Tet-ON VSV-g EIAV 1.6E+06 PACK (Stewart et al., 2009) 
4.4E+05 PROD (Stewart et al., 2011) 
HEK293T Concatemer array technique (co-transfection of linearized 
plasmids). 
Tet-OFF VSV-g HIV-1 3.0E+07 PROD (Lee et al., 2012) 
HEK293T RD-MolPack system: Recombinant hybrid baculo-AAV vector 
for gagpol-rev with hygro resistance. VSV-g SIN-LVs 
transduction of env and transfer vector. 
N/A RD114-TR HIV-1 3.0E+05 PACK (Stornaiuolo et al., 2013) 
1.2E+06 PROD 
HEK293T Concatemer transfection. Clonal selection using antibiotics. Tet-OFF VSV-g HIV-1 1.0E+07 PROD (Wielgosz et al., 2015) 
HEK293FT HIV-1 Gagpol integrated via Cre recombinase-mediated 
cassette exchange (RMCE). Plasmids transfection. Clonal 
selection using antibiotics. 
N/A RDpro HIV-1 1.0E+06 PROD (Sanber et al., 2015) 
HEK293T Transfection. Clonal selection using antibiotics. N/A Cocal HIV-1 1.9E+06 PACK (Humbert et al., 2016) 
1.0E+06 PROD 
HEK293T RD-MolPack system: Recombinant hybrid baculo-AAV vector 
for gagpol-rev with hygro resistance. VSV-g SIN-LV 
transduction for tat and env with puro selection. Transfection 
for SIN-transfer vector with zeo selection. 






effectively! reduce! the! cost! of! manufacturing,! all! the! while! enhancing! the!
development!and!implementation!of!these!vectors!for!their!applications!in!late!
phase!clinical!trials.!To!the!best!of!our!knowledge,!one!report!to!date!has!been!
published! for!GMP6grade! large!scale!vector!production! for! the! treatment!of!
SCID6X1,! using! Throm! et! al.,! (2009)! VSV6g! stable! inducible! cell! line.! The!
production! strategy! utilizes! a! 50L! WAVE! bioreactor! (GE! Healthcare,! UK),!
which!consist!of!a!disposable!bag!chamber!that!can!be!rocked!mechanically!
to!facilitate!oxygen!transfer!and!fluid!mixing.!The!culturing!of!producing!cells!
onto! Fibra6Cel! discs! which! were! suspended! in! the! bioreactor! allowed! the!




syndrome! treatment! (Wielgosz! et! al.,! 2015).! In! this! report,! further!
improvements! in! the! producing! cells! were! achieved! by! the! addition! of! the!

















as!an! important! factor! in!LV!manufacturing! for!higher!overall!productivity!of!
viral! vectors! with! decreased! costs! of! goods.! In! biopharmaceutical!
manufacturing,!downstream!processing!is!estimated!to!account!for!75680%!of!!
operational! costs! (Kramberger! et! al.,! 2015).! Following! viral! supernatant!
harvest,!downstream!processing! is!vital! for! the!(i)!purification!of!viral!vector!
from! surrounding! contaminants! and! impurities! that! may! impact! safety! and!
efficacy,! (ii)! concentration! of! harvested! low6titre! viral! supernatants! for! gene!
therapy!applications!and!(iii)!final!vector!formulation!in!appropriate!buffer!for!
subsequent!use!and!stability!(Segura!et!al.,!2006b!Merten!et!al.,!2014).!Over!
the! past! several! years,! considerable! advancements! have! been! made! for!
vector! design! and! large! scale! production,! however! less! effort! has! been!
invested!in!the!development!of!purification!processes!to!handle!large!vector!
volumes.!As!gene! therapy!can!be!currently! regarded!as!an!emerging! field,!
regulatory! agencies! have! not! yet! defined! strict! guidelines! on! vector!























which! can! impact! intact! vectors’! functionality.! These! include! non6infectious!
physical!particles!which!may!be!(i)!intact!defective/empty!virions,!(ii)!particles!
lacking! the! glycoprotein! envelopes! or! (iii)! damaged! particles! (Yang! et! al.,!
2012).!Interestingly,!the!majority!of!virions!produced!from!host!cells!are!non6
infectious!physical!particles!(Thomas!et!al.,!2007).!The!ratio!of!transducing!unit!
(or! infectious! particle)! over! physical! particles! (TU:PP)! is! well! recognized!
parameter!of!vector!product!purity!(Zimmermann!et!al.,!2011)!and!the!reported!
ratio!for!HIV61!have!a!very!wide!range!of!1:100!(Bourinbaiar,!1994),!1:10,000!
(Klasse! and!McKeating,! 1993),! to! 1:100,000! (Klasse,! 2015).! The! reported!




particles!with! a!TU:PP! ratio! closer! to! 1! demonstrating! vector! efficacy.!Viral!
aggregates! and! soluble! envelope! proteins! can! also! be! found! in! viral!
supernatants,! which! have! been! shown! to! act! as! transduction! inhibitors! by!
competitive!binding!to!cellular!receptor!thus!competing!with!envelope!proteins!
on!infectious!particles!(Kwon!et!al.,!2003).!The!elimination!of!these!impurities!





DNA!plasmids!and! transfection!agent! from! transient! transfection!production!
process,! (iii)!host6cell!derived!elements!such!as!proteins!and!nucleic!acids,!




























and! process6related! contaminants! is! an! essential! prerequisite! for! any!
downstream!processing!schemes!of!viral!vectorsb!as!removal!of!serum!and!
derivatives! from! producer! cell! line! have! been! shown! to! prevent! immune!
responses! and! local! inflammatory! and! immune! responses! in% vivo! (Scherr,!
2002b!Baekelandt!et!al.,!2003)!as!well!as!decrease!transduction!efficiencies!ex%
vivo! (Yamada! et! al.,! 2003).! Therefore,! for! clinical! applications,! several!
purification!steps!must!be!undertaken!for!viral!supernatants!to!ensure!safety,!
quality! and! potency.! A! general! flow! outline! of! the! typical! steps! involved! in!
published!downstream!processing!schemes!is!shown!in!Figure!1.6.!Given!the!













technologies,! these! schemes! ultimately! aim! at! capturing! viral! particles,!
eliminating!contaminants!and!polishing!vectors!products,!depending!on!type!
of! virus! and! intended! application! requirements! in! terms! of! production! size!
(Schweizer!and!Merten,!2010b!Wolf!and!Reichl,!2011).!Few!complete!schemes!
are! described! in! the! literature! in! details! from! supernatant! harvest! to! final!
product,!with!overall!recoveries!in!the!literature.!A!summary!of!clinical6grade!
purification! ‘trains’! from!different! institutions!are! depicted! in!Figure! 1.7!with!
overall!yields!ranging!between!20640%.!Currently,!overall!yields!higher! than!
















scale! production,! this! is! accomplished! by! centrifugation! followed! by!






cell! debris! may! pose! a! challenge! for! single6step! filtration! methods.!
Alternatively,!a!depth! filtration!can!be!employed!which!consists!of!a! fibrous!






of! large! vector! volumes,!which! are! representative! of! clinical!material,! have!
been! demonstrated! with! efficient! debris! clearance! using! step! filtration! with!







for! therapeutic! applications! in% vivo! and! ex% vivo.! Therefore,! following!





for! subsequent! steps! and! thus! in! turn! decreases! the! size! of! required!
equipment!(columns,!vessels!and!pumps,!etc.).!!
1.3.4.4.1!Centrifugation!!




purify! and! concentrate! viral! particles! (Segura! et! al.,! 2006).! Although! very!
efficient! in! small! particle! sedimentation,! UC! suffers! from! several!
disadvantageous! for! large!scale!applications.! Its! long!processing! times!and!
harsh!hydrodynamic!shear!forces!required!for!viral!pelleting!have!been!shown!




viral! pellet! resuspension! (Zhang! et! al.,! 2001),! represent! UC’s! main!
disadvantageous!for!scaled6up!purifications.!And!finally,!the!use!of!this!method!
results! in! the! sedimentation! of! both! process!and!product! derived6impurities!
along! with! viral! vectors! thus! resulting! in! a! reduced! potency! of! LVs! and!
requirement!of!further!purification!schemes!for!their!removal!(Transfiguracion!
et!al.,!2003b!Slepushkin!et!al.,!2003).!Alternatively,!density!gradient!UC!(DG6
UC)! can! be! employed! for! the! concentration! and! isolation! of! particles,! with!
sucrose!and!cesium!chloride!being!the!most!widely!used!gradient!media!for!
LV!purification!(Segura!et!al.,!2005).!Although!this!powerful!method!enables!
the! separation! of!LVs! from!different! impurities! such!as! defective! vectors,! it!
suffers! from!several!disadvantageous!such!as! loss!of! infectivity!due!to!high!
viscosity!of!gradient!medium,!difficulty!to!scale6up,!with!long!processing!times!
and! requiring! technical! expertise! (Segura! et! al.,! 2006).! Therefore,! the!








concentration! due! to! its! gentle! conditions,! ease! of! scalability,! efficiency! in!
volume!reduction!and!adaption!to!GMP!manufacturing!(Segura!et!al.,!2006).!
Conveniently,! in! addition! to! vector! concentration! UF! provides! a! level! of!
purification! for! viral! supernatant! by! the! washing! off! impurities,! through! the!
enrichment!of!viral!particles!in!the!retentate!and!the!removal!of!solution!and!





buffer! for! subsequent! purification! steps! or! into! a! final! formulation! buffer!
(Merten! et! al.,! 2011).! Due! to! its! advantageous! properties,! UF/DF! are! the!
preferred!methods! employed! in! all! published! clinical! grade! LV! purification!
schemes!(Figure!1.7)!(Slepushkin!et!al.,!2003b!Truran!et!al.,!2009b!Merten!et!
al.,!2011b!Ausubel!et!al.,!2012b!Aiuti!et!al.,!2013).!Different! filtration!modes,!
such!as! dead6end!or! tangential6flow! filtrations! (TFF),! and!devices,! such!as!
hollow!fibres!or!cassettes,!can!be!employed.!Off!these,!TFF!is!the!most!widely!




The!purification! of! concentrated! viral! supernatant! is! required! to! obtain! high!
vector!purities!which!is!advantageous!for!clinical!applications.!This!purification!
step!can!either!be!preceding,!proceeding!or!even!coupled!to!the!concentration!










downstream! processing! of! biological! products! at! an! industrial! large! scale!
setting! due! to! its! efficiency! in! high! purity! yields.! An! increasing! number! of!
chromatographic!purification!of!viral!vectors!have!been!reported!over!the!past!
years! (thoroughly! reviewed! in! (Kramberger!et!al.,!2015)).!Different! types!of!
chromatographic! resins! have! been! evaluated! for! the! purification! of! LVs!
(Scherr,!2002b!Slepushkin!et!al.,!2003b!Kutner!et!al.,!2009b!Cheeks!et!al.,!2009b!
Lesch!et!al.,!2011b!Zimmermann!et!al.,!2011)b!and!their!recent!development!
and!mechanical! characteristics!will! be! thoroughly! covered! in!Section!7.2.2.!
Due! to! its!scalability,! reproducibility,! fast!processing! times!and!potential! for!
automation,! chromatographic6based! technologies! for! viral! purification! have!
been!employed!in!all!large6scale!clinical6grade!processes!(Figure!1.7).!
1.3.4.5.1.1!Anion!exchange!chromatography!!
Ion! exchange! chromatographic! techniques! exploit! the! charge! interactions!
between! viral! particles! and! ion! exchange! ligands! immobilised! on! a!matrix.!
Lentiviral!particles!have!an!overall!negative!charge!at!neutral!pH,!thus!allowing!
their! capture! by! positively! charged! groups,! making! anion! exchange!
chromatography! (AEX)! an! appropriate! method! of! viral! purification.! The!
simultaneous!selectivity!of!this!method,!while!allowing!for!concentration!of!the!
feed,! has! rendered! AEX! as! the! most! widely! used! technique! for! current!







efficient! in! isolation,! one! of! the!main! disadvantages! of! this! method! is! the!
requirement!of!high!salt!concentration!(0.5!61!M!NaCl)! for! the!desorption!of!
captured! viral! particles.! As! discussed! in! section! 1.3.2,! LVs! functionality! is!





demonstrated! that! either! stepwise!gradient! elution! (Marino! et! al.,! 2015),! or!
stepwise!elution!coupled!with!immediate!virus!dilution!post6chromatographic!





and! its! respective! ligand! bound! to! the! matrix.! It! relies! on! specific! and!




provides! an! increased! product! yield,! while! reducing! the! number! of! steps!
currently! required! for! vector! purification,! thus! decreasing! the! cost! of!




containing! vector6binding! peptides! isolated! by! phage! display! screening!
(Fernandes! et! al.,! 2016).! However,! even! though! the! latter! is! a! powerful!
technology! for! the! isolation!of!RV!specific!peptides,! its! limitations! lies! in! the!
desorption! of! subsequent! captured! vectors! from! resin.! As! for! the! affinity!
chromatography! of! LVs,! few! reports! have! been! published! in! the! scientific!
literature!and!are!summarized!in!Table!1.6.!As!there!are!no!specific!LV!ligands,!
published!reports!have!utilized!vectors’!natural!abilities!to!bind!generic!ligands!
such! as! heparin.! After! the! capture! of! vectors! from! clarified! supernatants,!
elution!using!350mM!NaCl!resulted!in!53%!recovery!of!infectious!virus!(Segura!
et!al.,!2007).!Alternatively,!LVs!have!been!engineered!to!express!affinity!tags!
on! their! surface! such! as! hexahistidine! for! immobilized! metal! affinity!








and! biotin! system! has! been! used! by! labeling! viral! particles! with! a! biotin!
analogue,!desthiobiotin,!allowing!purification!from!monomeric!avidin!columns.!
Seeing!that!this!analogue!binds!avidin!at!a!lower!affinity!than!biotin!(Hirsch!et!
al.,! 2002),! the! loading! of! 2mM! biotin! onto! the! column! of! captured! vectors!

















































size! of! LV! particles! for! their! separation! in! a! non6adsorptive! manner.! LV!
particles! are! generally! recovered! in! the! void! volume! of! the! column,! while!










exchange! into! vector! formulation! solution! (Figure! 1.7).! In! one! study,! this!
method!was! reported!as! the!main! purification! step! for!VSV6g!pseudotyped!
retroviral!particle!but!was!however!preceded!with!UC!and!proceeded!with!a!
second!concentration!step!by!UF!(Transfiguracion!et!al.,!2003).!The!use!of!this!
method! therefore! is!dependent!on! the! levels!of! impurities!clearance!of!any!
purification!process!or!scheme.!!
1.3.4.6% Nucleic%acid%digestion%%
Due!to! the!nature!of! their!current! transient!production,!LV!supernatants!are!
contaminated! with! several! process6! and! product6related! impurities,! with!
nucleic!acids!representing! the!major!contaminant! (Sastry!et!al.,!2004).!This!




potentially! induce! an! immune! response! (Pichlmair! et! al.,! 2007).! Moreover,!
DNA!impurities!may!cause!difficulties!in!the!different!steps!of!vector!purification!
by!increasing!sample!viscosity!(Segura!et!al.,!2013).!Importantly,!the!physical!





importance! of! DNA! elimination! is! highlighted! by! the! fact! that! Benzonase®!
treatment!is!used!in!all!clinical6grade!downstream!processing!schemes,!albeit!






nuclease! is! necessary! and! represents! a! another! limitation! for! all! vector!
downstream!processes!(Merten!et!al.,!2016).!The!introduction!of!the!nucleic!
acid! digestion! step! early! in! the! schemes!may!maximize! the! removal! of! its!
impurities!by!subsequent!steps!such!as!TFF!or!SEC!(Merten!et!al.,!2011).!The!
nuclease! treatment! of! unconcentrated! large! vector! volumes! requires! an!
increased!amount!of!enzyme!required.!which!represents!another!limitation!as!
it! inevitable! increase! in! vector! manufacturing! cost! (Schweizer! and!Merten,!
2010)!!
1.3.4.7% Sterile%filtration%and%formulation%%
The! last! operating! step! in! most! clinical6grade! schemes! is! typically! sterile!
membrane! filtration! through!0.2µm! of! purified! vector! products! (Figure! 1.7).!
However,!significant!viral!losses!have!been!reported!as!a!consequence!of!the!
filtration! of! ~120nm! particles! into! 200nm! pores! (Segura! et! al.,! 2013).!
Consequently,!this!step!is!omitted!in!certain!vector!manufacturing!protocols!by!
ensuring! sterilisation! through! their! downstream! processing! (Ausubel! et! al.,!
2012).!More!importantly,!post6processing,!LVs!are!typically!stored!at!680°C!for!
protection! from! thermal! inactivation.! As! such,! viral! vectors! require! to! be!
formulated! in!a!buffer! that!can!ensure! functional!stability!during!storage!by!
reducing! viral! loss! and! retaining! infectivity.! However,! possibly! due! to! their!
infancy! as! therapeutic! vectors,! very! few! reports! investigating! these! critical!
aspects!of!product!formulation!have!been!published!in!the!scientific!literature.!
To!date,!vector!have!been!formulated!in!cell!culture!media!used!for!ex%vivo%cell!
culture,! such!as!CellGenix’s!CellGro®!and!Lonza’s!X6vivoTM! (Merten!et! al.,!
2011b!Aiuti!et!al.,!2013b),!which!contain!a!mixture!of!both!sugars!and!proteins,!
potentially! offering! some! degree! of! cryoprotection! for! viral! particles.!
Interestingly,! formulation!using!a!histidine!hydrochloride!based!buffers!were!
recently!shown!to!maintain!up!to!74%!of!starting!vector!titres!after!8!days!at!
25°C! (Fan! et! al.,! 2015).! Given! their! complex! biology! and! their! inherent!
instability,! optimisation! of! viral! vector! formulation! would! inevitably! aid! the!









schemes! employ! several,! at! least! 4,! technologies! in! clinical6grade! LV!
downstream!processes,!which!are!cumbersome,!time!consuming,!require!both!
technical! expertise! and! equipment! and! generate! ~! 30%! overall! yield!
(Rodrigues!et!al.,!2007b!Segura!et!al.,!2013).!Thus,! the!currently!employed!
purification! schemes! for! LVs! downstream! processing! represent! the! main!
bottleneck!for!the!clinical!and!commercial!progression!of!these!vectors!(Merten!
et!al.,!2014,!2016).!
The! lack! of! a! simple! and! selective! LV! purification! method,! with! efficient!
adsorption! and! mild! desorption,! was! the! basis! behind! this! project.! The!
selective! capture! of! labile! LV! particles! by! a! vector6specific! affinity! peptide!














•! To! develop!and! validate! a! cyclical6synthetic!peptide! for! efficient! and!






























junctions! that! are! complementary.! This! occurs! in! two! PCR! reactions! as!
depicted!in!the!below!schematic!Figure!2.1,!whereby!in!a!primary!PCR!reaction!
(Table%3)!sequences!of!DNA!are!amplified!with!overlapping!base!pairs!at!their!
extremities.! Subsequently,! in! a! secondary! PCR! reaction! complementary!
sequences! overlap! and! by! amplification! result! in! fusion! of! the! two! DNA!
sequences.!Due!to!its!3’!to!5’!proof!reading!activity,!Phusion!polymerase!(NEB!
M0530L)!was!used! for!all! PCR! runs,!with! its! 5X!High!Fidelity! buffer! (NEB,!
B0518S),! in! the! following! conditions:! initial! denaturing! and! polymerase!
activation!at!98°C!for!120sb!followed!by!a!36step!cycle!repeated!for!35!time:!
denaturing!at!98°C!for!40s,!primer!annealing!at!65°C!for!40s!and!polymerase!
extension!step!at!72°C! for!1min! /! kb!with!a! final!polishing!step!at!72°C! for!
10min.!PCR!products!were! separated!by! gel! electrophoresis! and!extracted!
using!QIAquick!Gel!Extraction!kit!(Qiagen!28704).!Primary!overlapping!PCR!
products!were!then!combined!together!is!a!secondary!PCR!reaction!using!the!














To! assess! and! screen! transformed! clones,! DNA! was! prepared! as! follows:!
single!colonies!from!bacterial!transformation!were!picked!from!agar!plates!and!







2506!500µL!of!correct!small! scale!bacterial! culture!and! incubated! for!16618!
hours! in! a! bacterial! shaking! incubator! at! 37°C! with! 220! RPM.! DNA! was!









contamination.! Concentrating! and! purity! of! plasmid! DNA! was! determined!
using!a!nanodrop!ND61000!spectrophotometer.!!
2.1.1.4% Restriction%endonuclease%digestion%%
Restriction! digests! were! performed! according! to! manufacturer’s! protocol!
(NEB)! in! order! to! generate! cloning!DNA! fragments!with! ‘sticky’! compatible!
ends!to!allow!DNA!ligation.!For!inserts!generated!by!PCR,!the!entire!sample!
was!used!after!PCR!clean!up,!whereas!for!its!corresponding!vector!backbone,!
5ug! of! plasmid! DNA! was! used.! In! both! instances,! reaction! volumes! were!
adjusted!with!molecular!grade!water!such!that!the!final!reaction!volume!was!
100µL.!For!double!digests,!buffer!selection!was!defined!by!manufacturer!with!
a! final! enzyme! concentration! of! 5%!v/v!of! the! final! reaction! volume.! In! the!




Size! verification! of! PCR! products,! restriction! digested! DNA! plasmids! and!
fragments! was! accomplished! by! DNA! separation! using! agarose! gel!
electrophoresis.!1%!agarose!gels!were!prepared!in!1x!TBE!buffer!with!agarose!
solubilisation!achieved!by!microwave!heating!of! the!solution.!Subsequently,!
the! melted! agarose! was! cooled! and! 0.561µg/mL! of! ethidium! bromide! or!

















was!used!according! to!manufacturer’s! instructions! to! remove! contaminants!
from!samples!before!downstream!usage.!!
2.1.1.8% DNA%ligation%%




































mixtures! with! SOC! medium! (NEB,! B9020S)! at! 37°C,! 220rpm! for! 30mins.!
Subsequently,! transformed!bacteria!were!spread!on!LB6agar!plates! infused!




The! adherent! cell! line! HEK293T! was! cultured! in! sIMDM! (Lonza! 126726F)!
supplemented! with! 10%! FCS! (Biosera,! FB1001/500)! and! 1%! Glutamax!




harvested! and! trypsin! was! inactivated! by! washing! the! flask! with! 10mL! of!












Engineered! cell! lines!were! cryopreserved! for! long! term! storage!as! follows:!
during!optimal!growth!conditions,!cells!were!harvested!and!after!centrifugation!
pellets!were!resuspended!at!5x106!cell/mL!in!chilled!cryopreservation!medium!
(Lonza)!and!aliquoted! into!1mL!aliquots! in!cryovials! (Corning).!Tubes!were!
placed!in!a!Mr.!Frosty™!freezing!container!which!was!stored!in!at!680°C.!The!




to! actively! metabolizing! cells! during! recovery.! Cryovials! were! thawed! by!
suspension! in!a!37°C!water!bath!and! immediately!washed! in!25mL!of!pre6














Plate% GeneJuice%(µL)% Media%(µL)% DNA%(µg)%
10cm% 30! 470! 12.5!






Taking! 10cm! plate! conditions! as! reference,! transfection! mixtures! were!
prepared!as!follows:!30µL!of!Genejuice!was!added!to!470µL!of!plain!media!for!
























overnight! with! both!monoclonal! antibodies!MACS!GMP!CD3! (OKT3! clone,!
Miltenyi!Biotech,!17060766116)!and!CD28!(15E8,!clone,!17060766117)!at!0.5!
















confluency! was! assessed! by! microscopic! examination! to! ensure! optimal!
density!for!transfection!of!50660%!confluence.!Transfection!mixture!containing!
470µL!plain!media!and!30µL!GeneJuice!were!prepared!for!each!plate!to!be!
transfected.! Following! 5! minute! incubation,! a! total! amount! of! 12.5µg! of!




envelope,! 3/8! retroviral! SFG6based! vector.!Mixtures!were! incubated! for! 15!




Stable! protein! expression! in! HEK293Ts! was! achieved! by! γ6retroviral!
transduction.!Briefly,!1x106!cells!were!seeded!in!66well!plate!and!24!hours!later!
1mL!of!VCM!was!gently!added!onto!cells!with!5µg/mL!of!Polybrene!(Merck!
Millipore,! TR610036G).! Once! cells! had! recovered,! cultures! were! passages!
twice!before!functional!usage.!!
2.3.1.3% γPRV%transduction%of%suspension%cell%lines%%






minutes! to!enhance! infectivity!by!spinoculation!and! then! incubated!at!37°C!
















of! gagpol! polyprotein! (Ikeda! et! al.,! 2003)b! 26! pMD2.G,! VSV6g! envelope!
expression! plasmid! (Naldini! et! al.,! 1996)! and! 36! pALF,! MLV6A! expression!
cassette,! both! of! which! were! kindly! provided! by! Prof.! Wassem! Qasim!
laboratory.!Depending!on!which!pseudotyping!glycoprotein!was!used,!VCM!
were!harvested!either!48!hours!or!48!and!72!hours!post6transfection!for!RDpro!
and! VSV6g/MLV6A! pseudotyped! LVs,! respectively.! Collected! VCM! were!






before! viral! purification,! 20%! sucrose! was! prepared! in! 50mM! sodium!






balanced! to! 0.1g! and! carefully! inserted! with! the! rotor! into! pre6chilled!
ultracentrifugation!machine.%Tubes!were!spun!at!23,000!rpm!for!2!hours!at!4°C!













The! infectious! titre! of! each! vector! preparation! was! determined! by! flow!
cytometric!analysis!of!eGFP!expression! following! transduction!of!HEK293T!
cells.!1!x!105!and!5!x104!cells!were!seeded!in!wells!of!66well!and!246well!plates,!
respectively,! in! 1mL!with! 5µg/mL! of! Polybrene.! To! determine! the! count! of!
infectious! units,! only! transduction! efficiencies! between! 1! –! 25%! of! eGFP!
positive!cells!can!be!taken!into!account.!RDpro/MLV6A!LV!and!VSV6g!LV!viral!
supernatants! were! serially! diluted! into! 3! and! 6! fractions! at! 1:5! and! 1:10,!
respectively,! in!cell!culture!medium!supplemented!with!Polybrene.!250µL!of!
each! dilution! was! added! into! each! well! for! transduction.! 72! hours! post6
transduction,! cells! were! trypsinized! using! cell! dissociation! solution! (Sigma,!
C5914)!and!resuspended!in!PBS.!eGFP!expression!was!analyzed!then!by!flow!
cytometry!using!BD!LSR!Fortessa™!X620!cell!analyzer!and!Flowjo!software.!
Viral! titres!were! calculated! from! virus! dilution!with! transduction! efficiencies!
between!1!–!20%!eGFP!expression!using!the!following!formula:!
!"#$%& ' ()*+, = . /01. 13.4$55&.6#.#%60&784#"10. ×.%.$;<=.>1&"#"?$.4$55&100 B(DEF.?158*$.(*+).× .7"58#"10.364#1%) !
2.3.2.3.2!p24!ELISA!!
Physical!particles!of!LV!samples!were!determined!by!measuring!p24! levels!
using! enzyme! linked! immunosorbent! assay! (ELISA).! The! QuickTitreTM!
Lentivirus!Titre!was!used! to!specifically!determine! lentivirus6associated!HIV!
rather!than!free!p24!proteins!(Cell!Biolabs,!VPK61076T).!The!manufacturer’s!
protocol! was! followed! and! samples! were! assayed! in! duplicates.! After! the!
incubation!with!kit’s!ViraBindTM!reagents!and!virus!inactivation,!the!principle!of!
the!assay!is!based!on!the!binding!of!p24!to!anti6p24!antibodies!coated!on!a!
microwell! plate.! This! is! followed! by! incubation! with! a! secondary! FITC6
conjugated!anti6HIV1!p24!monoclonal!antibody!(1:1000).!Subsequently,!wells!


















purification! using! Invitrogen’s! Quant6iTTM! PicoGreen®! dsDNA! Assay! kit!














using! SilverXpress! kit! (Invitrogen,! LC6100).! First! denatured! samples! were!
resolved!by!protein!electrophoresis!on!pre6casted!1.0mm!NuPAGETM!Novex!
4612%!Bis6Tris!Gels!(Invitrogen,!NP0322BOX).!For!denaturation!of!samples,!





contains! lithium! dodecyl! sulfate! allowing! maximum! efficiency! of! reducing!
agent.!Final!sample!volume!of!20µL!was!achieved!by!adding!ddH20.!Samples!
were!then!incubated!at!90°C!for!10!minutes!followed!by!ice!incubation!for!263!







which! has! a! threshold! of! 300! pg/mL! (Cygnus! Technologies,! F650).! The!









for! 30! minutes! at! room! temperature! without! shacking.! Absorbance! was!











antibodies! or! appropriate! ligands! then! washed! again! and! resuspended! in!
FACS!buffer!and!placed!on!ice!pending!analysis.!When!multiple!staining!steps!
were!required,!samples!were!washed!with!PBS!in!between!individual!staining!
steps! to! remove! unbound! antibodies.! Non6transduced/non6transfected!





fluorophores! into!adjacent! channels! can!occur! leading! to! false! positive.! To!
avoid! this! problem,! compensation! was! required! whereby! single6stained!
samples!which!were!both!beads!(OneComp!eBeads,!eBioscience)!and!cells!









100µg/mL! normocin.! Sterile! FACS! tubes! were! prepared! containing! sterile6
filtered!FCS!supplemented!with!100µg/mL!normocin! for!collection!of!sorted!















All! incubation! steps! were! performed! at! room! temperature! unless! stated!


















































As! the! aim! of! this! project! was! to! develop! an! affinity6based!method! for! LV!
purification! based! on! the! biotin! and! streptavidin! systemb! in! this! chapter,!
different!surface!expressing!streptavidin!binding!peptides,! i.e.!biotin!mimics,!




An! important!aspect!of!affinity6based!purification! is! the!use!of!a!simple!and!
efficient! method! that! would! allow! high6throughput! approaches! for! the!
purification!of!target!proteins6!or!viral!vectors!for!the!purpose!of!this!project.!
Numerous! genetic! affinity6based! methods! have! been! developed! for! the!
purposes! of! protein! purification.! These! are! primarily! based! on! the! use! of!
specific!antibodies!or!affinity!tags!that!are!fused!to!target!proteins!(Jarvik!and!
Telmer,! 1998b! Rigaut! et! al.,! 1999).! Among! the! different! affinity6based!






















affinity! for! biotin! –! in! the! femtomolar! range! (10615)! (Green,! 1990).! This!
represents! the! strongest! non6covalent! interaction! known! in! nature!which! is!
several!orders!of!magnitude!higher!than!the!affinity!of!commonly!used!affinity!





(Boer!et!al.,!2003).!Due! to! these!unique! features,! this!versatile!system!has!





covalently! bound! to! specific! lysine! residues! in! several! carboxylases,!which!
catalyse!pathways! involved! in! fatty!acid!biosynthesis,!gluconeogenesis!and!
tricarboxylic! acid! cycle! (Zempleni! et! al.,! 2008).! In! mammalian! cells.! biotin!




coin.! They! share! only! 30%!of! their! amino!acid! sequences!but! form! similar!






up! of! 8! anti6parallel! ß6strands! which! fold! into! an! up6down! barrel! with! four!
identical! ß6barrels! in! their! quaternary! structures,! each!with! a! biotin6binding!
pocket.! Both! proteins! exhibit! high! stability! against! heat,! pH! changes,!
denaturing! compounds! and! proteolytic! enzymes! (Wilchek! et! al.,! 2006).!
Moreover,!to!date!streptavidin!homologues!have!been!found!in!several!species!
such!as! fungus,! bacteria! and! frogs! (Jain!and!Cheng,! 2017)! but! none!have!
been!found!to!be!endogenously!expressed!in!mammalian!tissues.!However,!
despite! these! similarities! there! are! distinct! structural! differences! between!







isoelectric! point! of! ~6! resulting! in! negligible! non6specific! binding,! making!








Streptavidin! subunits! are!not! actually! independent,!with! functional! interplay!
occurring! between! adjacent! subunits! for! ligand! binding! (subunit! 1! and! 3!
interact!with!2!and!4,!respectively!in!an!identically!manner),!owing!to!the!highly!
conserved! Trp120! (Sano! and! Cantor,! 1995).! Upon! ligand! binding! in! one!
subunit! pocket,! Trp120! from! its! adjacent! subunit! helps! to! stabilise! biotin!
binding.!Therefore,!even!if!streptavidin!folds!into!a!tetramer,!it!can!be!regarded!





biotin! binding.! Quaternary! structures! of! biotin! binding! pockets! have!
complementary!shapes!to!biotin!and!are!lined!with!a!mixture!of!hydrophobic!
and!polar!residues!that!are!key!in!stabilising!ligand!binding.!Residues!Val47,!
Trp79,! Thr90,! Trp92,! Trp108! and! Leu110! form! a! hydrophobic! pocket! and!
interact! with! ligand! through! Van! der! Waals’! forces.! Upon! ligand! binding,!
biotin’s!urea!domain!forms!hydrogen!bonds!with!Asn23,!Ser27,!Ser45,!Tyr43,!






an!open,! flexible,! semi! disordered! confirmation! (Figure! 3.1b6c,! blue! chain).!
Upon!ligand!binding,!the!loop!closes!on!the!binding!pocket,!adopting!a!more!
stable! conformation! due! to! electrostatic! and! hydrophobic! interactions! with!
biotin!(Figure!3.1c,!red!chain)!(Freitag!et!al.,!1997b!Perbandt!et!al.,!2007b!Song!
et!al.,!2015).!The!importance!of!this!loop!in!ligand!binding!affinity!is!highlighted!




of! streptavidin! mutants! with! varying! properties,! such! as! traptavidin! (S52G,!
R53D)!that!exhibits!a!106fold!lower!dissociation!constant!(Chivers!et!al.,!2010,!
2011).! Intriguingly,! deletion! and!mutagenesis! experiments! on! binding! loop!
residues!have!shown!that!the!loop!is!not!required!for!association,!but!accounts!
for! the!high!affinity!binding!of!biotin,! through! the!modulation!of!dissociation!















of!biotin.% (b)%monomeric! subunit! of! streptavidin,!highlighting! the! flexible! loop! in!an!
open! (blue)!and! closed! (red)! conformation.% (c)%Schematic! diagram! of! immobilised!
tetrameric! streptavidin,! in! the! absence! of! its! natural! ligand! with! flexible! loops! of!








system! for! various! protein! and! cellular! applications,! such! as! detection,!
bridging,!isolation,!targeting,!immobilization,!and!imaging!(reviewed!in!Laitinen!
et! al.,! 2007b! Dundas! et! al.,! 2013b! Jain! and! Cheng,! 2017).! In! all! of! these!
systems,! one! component! is! labelled! with! either! 16! biotin! or! one! of! its!







recombinant!proteins! and!antibodiesb!where!biotin! is! covalently!attached! to!
amino! acid! side! chains! of! target! proteins! in! a! non6specific! manner.! This!
method! required! further! purification! steps! and! has! been! shown! to! cause!
inactivation! of! labelled! proteins! (Stolz! et! al.,! 1998).! As! a! result! enzymatic!
biotinylation!was!developed!and! its!use!was! first!described! in!bacterial!and!
yeast! expression! systems! (Cronan,! 1990)! and! then!adapted! in!mammalian!
cells,!requiring!the!genetic!engineering!of!a!biotin!acceptor!peptide!(BAP)!to!
target!proteins!(Parrott!and!Barry,!2001).!Once!translated,!BAP!fused!to!target!
protein! is! then! covalently! biotinylated!by! cellular! or! exogenously6expressed!
biotin!protein!ligase!(BPL),!with!bacterial!ligase!BriA!most!commonly!used!in!
living!cells!(Beckett!et!al.,!1999b!Fairhead!and!Howarth,!2015).!Unlike!chemical!




smaller! peptides! that! can! be! either! fused! to! target! proteins,! such! as!
commercially!available!Avitag!(Fairhead!and!Howarth,!2015),!or!expressed!as!
a!cell!surface!protein!such!as!Lodavin!(Murugan!et!al.,!2012)!for!strept(avidin)!







al.,!2004).!Therefore,!for!purification!application,!biotinylation! is!not! ideal! for!
the! isolation! of! labile! macromolecules.! To! benefit! from! nature’s! strongest!




Synthetic! peptides! have! proved! to! be! a! very! powerful! tool! for! numerous!
biotechnology! applications.! Small! peptides,! usually! discovered! by! phage!
display,! that!are!able! to! interact!with!a!protein’s!natural! receptor!are!called!
peptide!mimics!or!mimetopes.!There!are!obvious!advantages!of!fusing!target!
proteins!to!small!artificial!mimetopes!compared!to!larger!sequences!such!as!
BAP! for! streptavidin! binding.! Firstly,! small! peptides! do! not! require! the! co6
expression!of!exogenous!proteins!or!are!not!dependent!on!endogenous!biotin!
ligases! for! receptor! binding.! Secondly,! they! are! less! likely! to! affect!
conformational!structure!or! functionality!of! resulting! fusion!proteins.!Thirdly,!
these!peptides!are!not! likely! to!be!biotinylated!by!endogenous!biotin! ligase.!
Lastly,! small!peptides!are!very!easy! to!synthesise!or!produce!by!molecular!







for! affinity! purification! and! immobilisation! technologies.!Since! the! affinity! of!
biotin! is! too! strong,! affinity! of! peptide!mimics! could! be! fine6tuned! through!















constants! determined! in! the! millimolar! range,! whereas! biotin! binds! with!
femtomolar!affinity,!these!peptides!are!ideal!for!affinity!purification!applications!
as! they! can! be! easily! displaced! from! streptavidin! binding! pocket! by! biotin.!
Thus,! the! fusion!of!HPQ!containing!peptide! to! target!of! interest,!which!can!
range! from! a! protein! to! a! viral! particle,! should! first! allow! their! binding! to!
streptavidin! matrix! resulting! in! their! capture.! Subsequently,! with! orders! of!













Intriguingly,! both!molecular! similarities! and! differences! have!been! reported!
between!receptor!binding!of!HPQ!motif6containing!peptides!and!biotin.!In!the!
former! case,! residue! H! forms! hydrogen! bond! with! Ser88,! as! does! the!
carboxylate!domain!of!biotin.!Streptavidin!Ser45,!which!is!involved!in!biotin’s!
urea! domain! binding,! interacts! with! residue! P! on! its! carboxyl! terminus.!
Moreover,!residue!Thr90!in!streptavidin!forms!hydrogen!bonds!with!Q!residue.!








Many! advancements! in! peptide! development! have! been! made! since! the!







Trp6Arg6His=Pro=Gln6Phe6Gly6Gly)! (Schmidt!et! al.,! 1996).! Its! first! derivative!
was!shown!to!only!be!functional!when!placed!on!the!carboxyl!terminus!of!fused!
proteins.! Molecular! analysis! of! streptavidin! interaction! indicated! that! the!
peptide! did! not! penetrate! as! deep! into! the! binding! pocket! as! biotin! does.!
Moreover,!the!carboxyl!terminal!glycine!adopted!a!conformation!forming!a!salt!
bridge!with!Arg84! in!streptavidin!explaining! the!reason!behind! its! restrictive!
location! to! the! carboxyl6terminus.! In! an!effort! to! develop!a! peptide!with! no!
locational! restrictions,! Streptag6II! was! generated! with! a! carboxyl! lysine!
preceded!by!a!glutamic!acid,!which!it’s!side!chain!interacts!with!streptavidin!in!
a!similar!fashion!to!C6terminal!glycine!in!original!Streptag.!However,!Streptag!
had! a! slightly! lower! binding! affinity! for! streptavidin! than! Streptag6II.! Thus,!
authors!randomly!mutated!residues!44!6!47! in!streptavidin’s! flexible! loop.!A!
streptavidin! mutant,! termed! streptactin,! in! which! amino! acids! ESAV! of! the!
binding!loop!were!changed!to!VTAR,!was!isolated!with!a!higher!binding!affinity!
to! Streptag6II.! (Schmidt! et! al.,! 1996b! Skerra! and! Schmidt,! 1999).! These!
substitution!mutations!were!shown!to!lower!the!conformational!entropy!of!the!
loop!by!freezing!it!in!an!open!state,!causing!a!106fold!decrease!in!the!KD!for!
Streptag6II! binding! from! 13! µM! to! 1.3! µM! i.e.! 106fold! increase! in! affinity!
(Korndörfer! and! Skerra,! 2002).! Furthermore,! authors! have! generated!
Streptag6III!which!consists!of!two!peptide!sequence!of!Streptag6II!flanked!by!
a! long! serine6glycine! linker! as! the! final! peptide! derivative! for! this! system!



















I! 8! WRHPQFGG! Carboxy6! 37!µM!














Nanotag15! 15! fMDVEAWLGARVPLVET! Amino6! 4!nM!
Nanotag9! 9! fMDVEAWLGAR! Amino6! 17!nM!





of! SBP6tag! mimics! was! an! 886mer! peptide! that! was! derived! from! mRNA!
display! in!vitro!selection!procedure!(Wilson!et!al.,!2001).!This! large!peptide!
was!further!optimized!to!generate!a!smaller!386mer!mutant!with!a!KD!of!2.5!–!
4.9! nM! to! streptavidin! (A.! D.! Keefe! et! al.,! 2001).! Binding! studies! have!









streptavidin! mutant,! SAVSBPM18! in! an! effort! to! retain! SBP! affinity! while!
decreasing! that!of!biotin!by!substitution!of! two! residues! important! for!biotin!
binding,!G48T!and!S27A!(Wu!and!Wong,!2013).!More!recently,!authors!have!
developed! a! stronger,! covalent6based! interaction! between! SBP6tag! and!
mutant! receptor! by! the! strategic! addition! of! cysteine! residues! in! both!
components!generating!SBP(A18C)!and!SAVSBPM32!(Fogen!et!al.,!2015).!
Nanotag! peptides! are! another! class! of! biotin! mimics! however! they! do! not!
harbor!the!HPQ!motif.!Three!derivatives!were!developed!with!lengths!ranging!
between!15!and!7!residues,!with!the!former!exhibiting!the!tightest!binding!with!
high! affinity! to! streptavidin! (Lamla! and! Erdmann,! 2004).! Although!Nanotag!
peptides! have! the! highest! binding! affinities,! with! KD! in! nanomolar! range,!
compared!to!other!streptavidin!binding!peptidesb!Nanotag!peptides!can!only!
be! fused!to! the!N6terminus!of! target!proteins.!Their!high!binding!capacity! is!
attributed!to!the!formylation!of!initiating!methionine!(fMet)!residue!in!peptides,!
thus!restricting!the!use!of!Nanotag!to!bacterial!production.!Protein!interaction!
studies! revealed! a! remarkable! resemblance! in! fMet’s!molecular! interaction!













(Kay! et! al.,! 1993).! Furthermore,! an! increase! in! peptide! ligand! affinity! was!




biotin! mimics! (McLafferty! et! al.,! 1993).! The! importance! of! these! bonds! in!
enhanced! binding! conformation! was! shown! by! the! significant! decrease! in!
affinity!once!treated!with!DTT,!which!breaks!disulphide!bonds,!compared!to!
linear! peptides! (Weber! et! al.,! 1995).! Although! phage! display! studies! have!
demonstrated! increased! stability! and! higher! binding! of! cyclical! flanked!
peptides,!current!streptavidin!binders!like!Streptag6II!and!SBP6tag!are!linear!
peptides.!To!date,!the!use!of!cyclical!mimic!as!streptavidin!binding!peptides!
has! not! been! tested! yet,! to! the! best! of! our! knowledge.! Thus,! given! their!
increased! binding! kinetics,! the! potential! of! these! cyclical! mimic! as! affinity!
































•! To! determine! cyclical! peptides’! optimal! ectodomain/transmembrane!
structure! for! lipid! bilayer! expression,! between! CD8α! stalk! and! GPI!
anchors,!for!highest!streptavidin!binding.!!
•! To!assess!biotin6mediated!reversible!binding!of!peptides!to!streptavidin.!!
•! To! establish! the! proof! of! principle! of! affinity! purification! by! testing!


























optimal!cell!surface!expression!structure!had!to!be! tested.!To! that!end,! the!
three! peptides!were! cloned! in! 4! different! structural! formats.! All! constructs!



















SFG!derived!from!Moloney!murine! leukemia!virus! (MoMLV).!Open! reading! frames!
were!clones!upstream!of!marker!gene!eGFP!expressed!using!an!IRES.!Four!open!
reading! frames! were! generated! for! each! binder:! (1)! Flush:! consisting! of! a! CD86












Figure% 3.4:% Diagram% of% streptavidin% binders% and% their% different% surface%






labelled! with! APC! conjugated! streptavidin.! For! comparison,! streptavidin!
binding! of! eGFP! positive! cells! was! analysed! and! expression! profile! and!
median! fluorescence! intensities! are! shown! in! Figure! 3.5a6b.! Expression! of!
epitopes!on!GPI!anchors!did!not! result! in!significant!streptavidin!binding!as!
seen! in!Figure!3.5c.! Interestingly,! peptides! expressed! in!a! flush! format! i.e.!




















are!presented! in!a!graph! (b)!and! in!a! table! (c)!±!standard!deviation! (SD)!of! three!




streptavidin! binding! compared! to! GPI! anchors,! with! the! highest! binding!
attributed!to!Ctag.!The!superiority!of!CD8α!stalk!for!streptavidin!binding!may!
be! due! to! difference! in! binding! efficiencies! as! well! as! peptide! expression!










Since! the! CD8α! stalk! resulted! in! optimal! properties! for! affinity! peptide! in!
surface!expression!and!Ctag!resulted!in!highest!streptavidin!binding,!we!tested!
the!efficiency!of!streptavidin!bound!Ctag6CD8!displacement!by!biotin.!To!that!
end,! HEK293T! cells! were! transiently! transfected! either! Ctag!expressed! on!
CD8α!stalk!(from!Figure!3.3)!or!an!irrelevant!proteinb!the!beta!chain!of!T!cell!





















Figure% 3.6:% Reversible% streptavidin% binding% of% Ctag% by% biotin% displacement.%
HEK293T!cells!were! transiently! transfected!with!SFG!plasmid!expressing!Ctag!on!
CD8α!stalk!(Ctag6CD8s)!or!a!control!SFG!plasmid!expressing!the!beta!chain!of!T!cell!
receptor!protein! (6ve,!negative! control),! both!of!which! co6express!eGFP.!48!hours!
post6transfection,!cells!were!stained!with!streptavidin6APC.!Cells!were!then!incubated!









transient! transfection! of!Ctag! construct! (from!Figure!3.3).! These! cells!were!
stained,! alongside! non6transfected! cells,! with! either! streptavidin6APC! or!
avidin6APC! ,48! hours! after! transfection! (Figure! 3.7).! As! expected,! Ctag!
exhibited! high! intensity! binding! to! streptavidin! with! around! 86%! ±0.3! cells!
positive!for!streptavidin.!Ctag!however!did!not!to!bind!avidin,!with!1.5%!±0.4!
cells!positive!for!avidin!staining!(Figure!3.7a).!Moreover,!streptavidin!positive!






















beads.! If! cells! with! much! larger! mass! were! successfully! purified,! then!
purification!of!viral!particles!should!be!possible!in!a!similar!manner.!K562!cells!




(pre6sorting)! was! achieved! based! on! eGFP! expression! (Figure! 3.8).!
Transduced! cells! were! then! incubated!with! superparamagnetic! streptavidin!
beads! that!are!commonly!used!for!various!applications,!MyOne!streptavidin!






isolation,! such! as! Miltenyi’s! streptavidin! microbeads.! Dynabeads! do! not!
require!customized!columns!for! isolation!of!bound!macromolecules!and!are!
large!enough! to! be!manipulated! in!magnetic! racks! that! can!hold! 1.5/15mL!
tubes.! A! cellular! pellet! containing! 1x106! Ctag6transduced! K562! cells! was!
incubated! with! an! excess! number! of! magnetic! beads! (~3.5! x! 107)! and!
incubated!for!1!hour.!Subsequently,!using!a!magnetic!rack,!magnetic!beads!
were!isolated!from!flow6through!fraction!into!sorted!fraction,!both!of!which!were!
cultured! separately! before! isolation! analysis.! Subsequently! 12! days! post6
sorting,!during!which!cells!were!passaged!to!remove!the!majority!of!magnetic!
beads! as! not! to! interfere! with! flow! cytometry! analysis,! the! sorted! fraction!
contained! 93.6%! of! eGFP6positive! cells,! whereas! the! flow6through! fraction!
was!depleted!from!eGFP6positive!cells!and!contained!97.4%!eGFP6negative!





SFG.Ctag.IRES.eGFP.! Transduction! efficiency! was! determined! by! flow! cytometry!
and!10.5%!of!the!cells!were!eGFP!(y6axis)6positive!(x6axis!of!plots!is!blank!to!account!




magnetic! beads! for! better! flow6cytometry! detection.! A! schematic! diagram! depicts!






In! this! Chapter,! we! have! constructed! and! validated! a! surface! expressing!
flanked!cyclical!biotin!mimic!(Ctag,!16aa)!as!an!affinity!purification! tag! from!
Giebel!et!al.,!(1995).!!
Ctag!contains! two!aspects!of!peptide!designs! that!were!shown! to!enhance!
binding! and! stabilize! structural! conformationb! flanking! HPQ! motifs! and!
constraining!it!in!a!cyclical!manner!(Kay!et!al.,!1993b!McLafferty!et!al.,!1993).!








on! these!anchors!may!have! resulted! in! limited!cell! surface!presentation! for!
receptor! binding! compared! to! the! distal! CD8α! stalk.! Moreover,! with! the!
difference! in! length! between! these! two! surface! structures,! it! could! be!
suggested! that! expression! on! CD8! increases! peptide! accessibility! to!
streptavidin,! thus! resulting! in! higher! binding.! However,! since! an! indirect!
measurement!was!performed!based!on!eGFP!expressionb!this!could!be!further!
investigated!by!determining!the!density!of!epitopes!expressed!on!both!CD8α!













higher! binding! intensity! of! Ctag! compared! to! sCtag.! However,! further!
experiment!determining!binding!kinetics!of!these!variants!would!elucidate!the!
impact! of! Ctag’s! further! flanking! residues.! Nonetheless,! in! this! chapter! we!
have! demonstrated! bound! Ctag’s! displacement! by! the! presence! of! biotin!
owing!to!its!extraordinary!affinity!to!streptavidin,!thus!demonstrating!reversible!
Ctag!binding!to!streptavidin.!
A! true! biotin!mimic! should! bind!all! biotin’s! natural! receptors.!However,! few!





and! streptavidin! have! certain! structural! differences.! Upon! ligand! binding,!
aromatic!residue!Phe72!in!avidin!plays!an!important!role!in!stabilizing!ligand!
binding.!This!residue!or! rather! its! interactions,!does!not!exist! in!streptavidin!
(Livnah! et! al.,! 1993).! Therefore,! HPQ! motif! may! not! be! able! to! form! the!
required!contact,!such!as!Phe72,!for!avidin!binding.!Furthermore,!avidin!does!
not!contain!a!residue!corresponding!to!Ser45,!which!plays!an!essential!role!in!
both! biotin! and! HPQ6motif! binding.! These! reasons! could! account! for! the!
preference! of! HPQ6containing! mimics! to! streptavidin! rather! than! avidin.!
Further! investigation! into! the!molecular! interactions! of! HPQ! to! streptavidin!
could!elucidate!its!full!interplay,!which!in!turn!would!highlight!key!features!that!
are!responsible!for!streptavidin!or!avidin!specific!binding!of!mimics!!
In! this! Chapter,! Ctag’s! binding! affinity! has! proven! to! be! sufficient! for! the!
capture!of!suspension!cells!using!streptavidin! labeled!magnetic!beads,!thus!






































packaging! cells’! membrane,! allowing! modification! incorporation! in! budding!










Upon!budding! from! infected!cells,! virions!are!surrounded!by!a! lipid!bilayer,!
termed!envelope.!This!layer!is!derived!from!the!packaging!cells!and!contains!
both!virus!and!cell6derived!proteins.!The!only!viral!proteins!on!this!surface!are!
envelope! glycoproteins! which! are! responsible! for! target! cell! receptor!
recognition!and!cell!entry! (Liang!et!al.,!2009).!Prior! to!budding,! the!precise!
location!and!mechanisms!of!viral!particle!assembly!are!not!fully!understood!
yet.! Nonetheless,! apart! from! viral! proteins,! particles! also! contain! host! cell6








It! is! rather!difficult! to!discriminate!between! type!2!and!3,!as! it! is!difficult! to!
demonstrate!the!former.!It!has!however!been!proposed!that!most!inclusions!





As! for! vector! surface! engineering,! the! field! has! widely! developed! and!
advanced!for!non6enveloped,!naked!viruses!such!as!AAV!and!AdV!due!to!their!
inherent!increased!particle!stability!(reviewed!in!Waehler!et!al.,!2007b!Buchholz!









This! concept! was! covered! in! Section! 1.3.1% and! involves! the! transfer! of!





et! al.,! 2003).! Nevertheless,! applying! the! methods! of! incorporation! of! cell6





during! virion! assembly.! A! later! study! then! proposed! an! indirect! model! for!
incorporation! involving! interaction!with!viral!protein,! thus!making! it!a! type!1!
incorporation!(Jorgenson!et!al.,!2009).!Unfortunately,!pseudotyping!is!limited!






made! for! targeted! transduction.!Many!polypeptides!such!as!growth! factors,!
cytokines! and! synthetic! peptides! have! been! displayed! on!RV/LV! envelope!
proteins!as!eitherb!N6terminal!fusions,!inserted!into!proline6rich!hinge!region!or!
even! as! N6terminal! substitution! (Larochelle! et! al.,! 2002).! In! these! studies,!
insertion! sites! had! either! been! determined! by! structural! information! of! the!
receptor’s!binding!domain!or!by!screening!a!large!pool!of!chimeric!mutantsb!or!
in! most! cases! it! was! determined! heuristically! (Rothenberg! et! al.,! 2001).!
However!these!attempts!were!met!with!several!difficulties!due!to!the!nature!
and!role!of!envelope!glycoproteins.!!
Murine! leukaemia! virus! (MLV)! ! glycoprotein! is! the! most! commonly! altered!
envelope! for! targeted! transduction! with! modifications! including! peptide!
insertion! in! pre6folded! domains! (Valsesia6Wittmann! et! al.,! 1994b!Wu! et! al.,!
1998b!Gollan!and!Green,!2002),!expression!of!peptides!as!additional!domains!
(Chadwick!et!al.,!1999b!Cosset!et!al.,!1995b!Fielding!et!al.,!1998b!Martín!et!al.,!
2002b! Maurice! et! al.,! 1999,! 2002)! and! peptides! fused! directly! to! the!





(Wu! et! al.,! 2010)! were! shown! to! have! poor! transduction! efficiencies.!




variable! fragment! (scFv)! on! its! amino6terminus! could! not! induce! fusion!
activation!and!subsequent!viral!entry!on!target!cells!(Zhao!et!al.,!1999).!This!
was!also!observed!when!EGF6MLV!greatly!impaired!infection!of!EGFR6positive!
cells! only! but! not! EGFR6negative! cells! (Cosset! et! al.,! 1995).! These!
observations! were! suggested! to! be! caused! by! receptor! sequestration! on!
plasma!membrane!followed!by!receptor6mediated6endocytosis,!which!routed!














surface!molecules.!Several! studies! investigating! the!molecular!mechanisms!
between!receptor!binding!and! fusion!activation!domains!of!envelop!proteins!
indicated! that! these! two! features! are! very! closely! coupled! with! highly!






Tai! et! al.,! 2003b! Verhoeyen! et! al.,! 2003).! However,! infection! rescue! for!







It! is!generally!accepted!that! loss!of! infectivity!of!pH6independent!engineered!
glycoproteins,! such! as! VSV6g! and! MLV,! is! caused! by! failure! of! inducing!
conformational! change! required! for! fusion! upon! cell! receptor! binding! for!
infectivity!by!fusion!(Larochelle!et!al.,!2002b!Metzner!and!Dangerfield,!2011).!
This! is! highlighted! by! the! fact! that! envelope! glycoproteins! that! use! a! pH6
















signal! sequence! (GSS)! at! its! carboxyl! end! is! recognized! by! transaminase!
enzyme!in!the!ER!which!processes!it!by!GSS!cleavage!and!replacement!with!
GPI6anchor.! A! wide! range! of! functions! can! be! attributed! to! GPI! anchored!
proteins! from! signal! transduction! (Haeryfar! and! Hoskin,! 2004),! human!
complement!regulatory!activityb!and!viral! infectivity!restriction!(Swiecki!et!al.,!
2013).!These!proteins!have!been!shown!to!frequently!associate!with!lipid!rafts!
(Legler! et! al.,! 2005).! Most! strikingly,! GPI! proteins! have! a! mechanism! of!








It! was! recently! demonstrated! that! the! lipophilic! parts! of! these! anchors! are!




dynamic! allowing! simultaneous! viral! painting! of! two! different! GPI! proteins!
(Metzner!et!al.,!2013b)b!as!well!providing!modified!viruses!with!new!functions,!
such! as! immune! protection! by! CD95! painting! (Heider! et! al.,! 2016).! Two!
strategies!have!been!developed!for!lentiviral!modification!using!GPI!proteins:!!
1.! Membrane! co6localization! at! possible! viral! budding! site! such!as! lipid!




Although! this! type! of! modification! is! highly! versatile,! GPI’s! inherent!
hypermobility! can! be! seen! as! its! own! Achilles’! heel,! as! its! reversible!
















feasibility! of! such! a! highly! versatile! and! flexible! bridging! adaptor! was!
demonstrated! in! 1989! with! biotinylated! antibodies! against! viral! envelope!
protein!and!target!cells’!MHC!II!molecules!(Roux!et!al.,!1989).!However,!viral!
entry! was! shown! to! occur! via! MHC!molecule,! which! resulted! in! low! gene!
transfer!as!RV!were!routed!via!another!endosomal!pathway.!Moreover,! the!




a! chimeric! protein! consisting! of! ASLV’s! cell! receptor,! which! binds! its!
glycoproteinb!fused!to!different!growth!factors!such!as!EGF,!VEGF!and!HRG,!
for!targeted!transduction!of!RV!to!cells!expressing!their!respective!receptors,!
such!as! tumor! cells! (Snitkovsky! et! al.,! 2000,! 2001b!Snitkovsky!and!Young,!
2002).!Moreover,!nanobody!can!be!used!instead!in!chimeric!proteins!for!target!
receptor! binding,! and! their! use! was! demonstrated! with! the! retargeting! of!
enveloped!HSV61! vectors! to! tumor! cells! bearing!CEA!antigen! (Baek!et! al.,!
2011).!Although!soluble!adaptors!offer!a!wide!range!of!versatility!for!virus6cell!




up! their! production! which! has! its! own! technical! difficulties! (Waehler! et! al.,!










their! extraordinary! affinity,! as! discussed! in! Section! 3.2.% For! example,!
monomeric!avidin!was!genetically! fused! to!membrane!anchoring!domain!of!
VSV6g,! which! upon! viral! incorporation! allowed! dual! imaging! and! targeting!
usage!(Kaikkonen!et!al.,!2009a).!This!method!is!attractive!as!using!envelop!
protein’s! membrane! stalk! would! allow! co6localization! of! chimeric! protein!
leading!to!viral!incorporation.!Other!approaches!have!utilized!biotin!acceptor!

















have! been! made! to! chemically! manipulate! enveloped! viruses! for! various!
applications.! For! example,! galactose!moieties!were! chemically! added! onto!
ecotropic!MLVs!which! led! to! targeted! transduction!of!human!hepatoma!but!
with!reduced!infectivity!(Neda!et!al.,!1991).!Moreover,!chemical!modification!
can! impose! a! new! function! of! particle! such! as! host’! immune! system!













with! particle! stability! or! function! leading! to! defective! infectivity.! Moreover,!
unbound! chemical!molecules!would! require! removal! by! another! step!which!




As!discussed! in!section!4.1.2,!modification!of!viral! vectors!can!be!used! for!
several! applications! such!asb! (i)! targeted! infection! of! specific! cell! typesb! (ii)!














ranging! between! 1006120nm,! thus! making! them! bionanotechnological!
devices.! It! has! been! proposed! that! such! modifications! thus! become!





particles! using! the! biotin6(strept)avidin! system! leading! to! particle!
functionalisation,!for!either!targeted!transduction!or!purification!of!vectors!and!
owing! to! the! versatility! of! this! system,! many! variations! have! been! applied!
(Chan!et!al.,!2005b!R.!Chen!et!al.,!2010b!Etemadzadeh!et!al.,!2015b!Kaikkonen!
et!al.,!2009bb!Lesch!et!al.,!2009b!Morizono!et!al.,!2009b!Nesbeth!et!al.,!2006).!
In! the! interest! of! this! project,! studies! that! have! utilized! streptavidin!
paramagnetic!beads!to!capture!biotin6modified!RV/LV!particles!and!along!with!
their!respective!efficiencies,!are!summarized!in!Table!4.1.!The!use!of!magnetic!
beads! as! adsorbent! particles! to! bind! biotin6modified! viruses! was! first!
demonstrated!by!Hughes!et!al.,!(2001),!resulting!in!selective!capture!of!90%!
of!infectious!modified!RV!particles.!Williams!et!al.,!(2005)!compared!different!
adsorbent! solid! phases,! including! magnetic! beads,! to! capture! chemically!
biotinylated!RVs.!The!highest! fold! increase! in!vector!capture!efficiency!was!




of! non6viral! BAP6fusion! protein,! using! MyOne! streptavidin! magnetic!
Dynabeads! (Nesbeth! et! al.,! 2006).! Furthermore,! another! study! biotinylated!






the! efficiency! of! capture! in! culturing! medium! containing! endogenous!
concentrations!of!biotinb!as!well!as!efficiency!of!release!of!modified!vectors!by!
free!biotin.!Chen!et!al.,!(2010),!addressed!this!issue!by!modifying!LVs!with!a!
biotin! analogue,! desthiobiotin! which! is! easily! displaced! by! biotin! due! to! its!














studies! nonetheless,! cumulatively! indicate! the! feasibility! and! potential! of!


















Type of  
LV modification 








RV Chemical biotinylation of 
vector packaging cells with 
biotin-NHS ester. 
Random  Streptavidin 
magnesphere, 
Promega 
90% (Hughes et 
al., 2001) 
LV Exogenous expression of 
non-viral proteins in vector 
packaging cell. Then, 
incubation of harvested viral 
supernatant with respective 





70% (Chan et al., 
2005) 
RV Chemical biotinylation of 





65% (Williams et 
al., 2005) 
LV Metabolic biotinylation of 
membrane bound fusion 




95% (Nesbeth et 
al., 2006) 
LV Genetically engineered 


















were! captured! using! different! streptavidin! magnetic! beads! and! efficiencies! were!









In! conclusion,! there! are! many! different! strategies,! individually! or! several!




bioprocessing.! Accordingly,! strategies! that! have! been! applied! for! LVs!
modification!with!biotin! for!example,! relied!on! ‘gentler’!methods! that!do!not!
alter!viral!proteins,!such!as!random!incorporation!of!biotinylated!proteins.!This!












!! The! advantage! of! this! method! would! be! its! potential!
simplicity! and! specificity! for! viral! incorporationb! since!
fusion! protein! would! express! RDpro’s! transmembrane!





!! This!method!should!allow! for! the! incorporation!of!Ctag6





affect! receptor! binding! or! infectivity! of! chimeric!
glycoproteins.!!
3.! Random/passive! incorporation! of! Ctag! onto! viral! surface! of! budding!
virions.!!
!! This! method! represents! the! easiest! technical!
modification.!However,!it!may!not!result!in!sufficient!Ctag!
expression! per! virion! to! allow! efficient! capture! by!
streptavidin!beads.!




















particles,! we! reasoned! that! the! surface! expression! of! the! peptide! on! the!
transmembrane!and!endodomain!of!viral!envelope!RDpro!could!allow!the!co6
localization! of! Ctag! and! envelope,! enabling! its! passive! incorporation! into!





non6transfected! cells! were! harvested! and! stained! with! streptavidin! (Figure!
4.2b).! As! expected,! cells! transfected! with! Ctag! on! CD8α! stalk! resulted! in!
streptavidin! binding!of! eGFP!positive! cells.!However,! cells! transfected!with!
Ctag!expressed!on!RDpro! transmembrane!and!cytoplasmic!domain!did!not!
exhibit! any! streptavidin! binding.! The! lack! of! streptavidin! binding! indicated!
absence!of!surface!expression!of!fusion!protein!highlighting!the!difficulties!in!
engineering!chimeric!surface!expression!structures.!Therefore,!the!strategy!for!







depicting! wild6type! Ctag! on! CD8α! stalk! and! fusion! protein! of! Ctag! with! CD8α!









manipulation! of! RD1146derived! envelope! has! never! been! tested.! Known!












These! constructs! were! first! tested! for! Ctag6engineered! envelopes! surface!
expression!by!transient!transfection!of!plasmids!in!293T!cells!along!with!Ctag6
CD8α!plasmid!as!a!control.!48!hours!post6transfection,!Ctag6CD8α!and! the!
two! engineered! MYC862A6RDpro! transfected! cells! were! stained! with!
streptavidin! alone! and! streptavidin! with! anti6MYC! antibody,! respectively!





functional! lentiviral! vector!production.!Third6generation! packaging!plasmids,!







due! to!Ctag!engineering! on! its! surface!unit,!or! (ii)! failure! of! inducing!either!
precursor! cleavage! or! fusion! due! to! peptide! insertion! into! RDpro’s!
transmembrane! domain! leading! to! a! defective! viral! envelope.! Therefore,!
although!addition!of!Ctag!onto!the!two!engineered!proteins!resulted!in!plasma!
membrane!mimic!expressions,! these!engineered!glycoproteins!on! their!own!










(a)% Schematic! diagram! of! 16wild6type! RDpro! protein! and! two! genetic! engineered!
variantsb!26Ctag6RDpro!with!peptide!inserted!on!its!N6terminus!after!protein’s!signal!
peptide!with!a!serine!glycine!linkerb!and!36RDpro6SU.Ctag.TM!with!peptide!inserted!





















the! surface! of! lentiviral! vectors! have! been! demonstrated.! So! far! in! this!
Chapter,!several!strategies!were!taken!to!modify!LVs!with!Ctag!expressed!on!
CD8α! stalk! with! failed! attempts.! As! a! third! option,! we! reasoned! that! high!
surface!expression!of!Ctag!on!virion!producing!cells!should!allow!its!passive!
incorporation!in!the!viral!envelope!in!the!same!manner!as!the!random!particle!
inclusion! of! host! cell! derived!membrane! bound! proteins.! High! stable! biotin!
mimic! expression! in! virus! producing! cells! would! be! achieved! through! γ6
retroviral! transduction.! Subsequent! transfection! with! lentiviral! packaging!
plasmids,! independently! of! these! components,! should! then!produce! virions!
that! acquire! Ctag! on! their! surface! while! they! are! budding! out! of! Ctag6
expressing!producer!cells.!(Figure!4.4).!!
!!
Figure% 4.4:% Random% incorporation% of% Ctag% peptide% on% LV% model.% Proposed!
hypothesis!on!the!production!of!Ctag6modified!LVs!by!random/passive!incorporation!














that! the!membrane! location!of!LV!virion!budding! from!host!cells! is!not!well!
understood,! it! was! important! to! assure! abundant! plasma! membrane!
expression!of!Ctag!on!the!CD8α!stalk.!Its!membrane!expression!was!shown!

















beads! thus! indicating! that! capture! of! modified! vectors! was! due! to! Ctag!
expression!on!their!surfaces.!To!demonstrate!this,!non6transduced!(NT)!and!
Ctag6293T! cells! were! transiently! transfected! with! second! generation! LV!
packaging! plasmids! pseudotyped! with! either! VSV6g! or! RDpro! and! viral!
supernatants! were! subjected! to! proposed! streptavidin! purification!
(Methodology! 1).! Cells! were! transfected! with! two! different! pseudotyping!
envelopes! to! determine! the! broad! applicability! of! such! a! method! in! an!
envelope6independent!manner.!!
%
Methodology% 1:% Preliminary% protocol% for% streptavidin=mediated% magnetic%
capture% of% LV% produced% from% Ctag=293T% cells.% Second! generation! packaging!
plasmids! were! transfected! into! both! NT6! and! Ctag6293T! cells! cultured! in!
supplemented!IMDM!(10%!FCS!+!1%!Glutamax).!Vector!contaiing!media!(VCM)!i.e.!
viral!supernatants,!were!harvested!48hours! later!and!processed!to!remove!cellular!
debris! by! centrifugation! and! ultrafiltration! using! 0.45um! filters! (Neat! fraction,! 1X!
volume).! Then! LV! supernatants! were! incubated! with! Dynabeads®! MyOne™!
Streptavidin!T1!magnetic!beads!(0.5!mg!beads!per!mL!of!LV!supernatants),!that!were!
previously!washed!with!PBS!5X!as!per!manufacturer’s!protocol!and!resuspended!in!
1X!cold! IMDM,! for!2!hours!at!4°C!with!gentle! rotation! in! falcon! tubes.!Afterwards,!
falcons!were!placed! in!magnetic! rack!and! left! to! stand! for! 1!min! followed! by! the!
separation! of! the! supernatant! from! immobilized! magnetic! beads! (Flow! Through!







to!dilute!out!magnetic!beads.!48!hours! later,! cells!were!harvested!and!stained! for!





LVs! pseudotyped!with! VSV6g! produced! from! both!NT6and!Ctag6293T! cells!
contained! functionally! infectious! viral! particles! as! indicated! by! the! high!
transduction!efficiencies!of!neat!(i.e.!crude!harvested!supernatant)!columns!of!
80.2%! and! 76.8%,! respectively! (Figure! 4.6a.1).! As! postulated,! target! cells!
transduced!with!purified!streptavidin!beads!(i.e.!beads!incubated!with!modified!
vectors!then!subjected!to!PBS!washes!by!magnetic!selection!and!release)!of!
































293T!cells.!Both! virus!supernatants! (NM6LV!and!Ctag6LV)!were! then!subjected! to!
streptavidin!beads!purification!as!depicted!in!Methodology!1,!with!column!fractions!




Fc! (ah6Fc6649)! antibody! to!determine! transduction! efficiencies!by! Flow!Cytometry!
(FACS).!Dot!plots!of!ah6Fc!vs!SSC6A!represent!cells!transduced!with!either!20μL!of!
VSV6G!and!50μL!of!RDpro!of!all!fractions!for!both!NM6LV!and!Ctag6LV.!Positive!cells!





Moreover,! given! that! the! scope! of! our! laboratory! involves! the! genetic!











to! either! be! due! to! non6tagged6LV,! streptavidin! bead! saturation! or! the!
presence!of!biotin!in!both!IMDM!(53.2nM!biotin,!provided!by!supplier)!and!the!
supplemented!FCS!(unknown!biotin!concentration).!Therefore,!an!optimized!
protocol! was! developed! to! address! all! of! the! above! and! is! depicted! in!





on! capture! efficiency.! Additionally,! to! determine! whether! remaining! viral!
particles! in! flow! through! fraction! of! Ctag6LV! purification! was! due! to! bead!
saturation!or!non6tagged!LV,!flow!through!of!the!1st!purification!was!subjected!







Methodology% 2:% Biotin=free% protocol% for% Ctag=LV% capture% using% streptavidin%
magnetic% beads.%LV! plasmids! transfected! NT6! and! Flankedccstreptag6293T! cells!
cultured!in!supplemented!IMDM!(10%!FCS!+!1%!Glutamax)!were!gently!washed!with!
PBS!24!hrs! post6transfection! and! cultured! in!plain!DMEM.! LV! supernatants!were!
harvested!24hour!later!and!processed!(Neat,!1X!volume).!LV!supernatants!were!then!
incubated!with!Dynabeads®!MyOne™!Streptavidin!T1!magnetic!beads!(0.5!mg!beads!
per! mL! of! LV! supernatants),! that! were! previously! washed! with! PBS! 4X! as! per!
manufacturer’s!protocol!and!resuspended!in!1X!cold!IMDM,!for!2!hours!at!4°C!with!
gentle!rotation!in!falcon!tubes.!Afterwards,!falcons!were!placed!in!magnetic!rack!and!




was! repeated!3X!and!beads!were! then! resuspended! in! cold! supplemented! IMDM!
(Purified!Beads!fraction,!1X!volume).!This!process!was!repeated!in!the!exact!steps!
but!with! the! Flow! Through! fractions! of! the! first! purification! for! a! second! round! of!
purification! with! streptavidin! beads.! All! fractions! (Neat,! Purified! Beads! and! Flow6
Through)! were! serially! diluted! and! added! onto! NT6293T! cells! in! the! presence! of!













successfully! completely! captured! by! streptavidin! beads! with! one! round! of!
purification!as!indicated!by!a!transduction!efficiency!of!27.5%!in!the!1st!purified!
fraction,!with!negligible!transduction!efficiencies! in!both! its! flow!through!and!
subsequent!fractions!of!2nd!round!of!purification!(Figure!4.7a).!This!purification!
method!was!Ctag6specific,!as!both!the!neat!and!1st!flow!through!fractions!of!
NM6LV! were! not! captured! by! streptavidin! beads,! giving! void! transduction!
efficiencies!in!both!the!1st!and!2nd!purified!beads!fractions.!These!results!were!
successfully!reproduced!in!three!independent!experiments!(n=3)!as!indicated!
by! the!viral! titres!plotted! in!Figure!4.7b,! in!which!neat!Ctag6LV!(1.7!±1!x105!
IU/mL)!are!recovered!in!the!1st!purified!bead!fractions!(1.66!±1.1!x105!IU/mL),!
with!no!statistical!significance!observed!between!these!fractions.!Neat!NM6LV!
(1.5!±0.4!x105!IU/mL)! followed!through! into! flow!through!fractions!of! the!2nd!
purification! (1.1! ±0.2! x105! IU/mL),! with! no! significant! difference! detected!

















RDpro! pseudotyped! LV! particles! encoding! a! eGFP! (pCCL.PGK.eGFP)! were!
produced! from! both! NM6! (Non6Modified6LV)! and! Ctag! (Ctag6LV)! 293T! cells.! Both!
negative!control!and!experimental!supernatants!were!then!subjected!to!streptavidin!
beads! purification! as! depicted! in! Methodology! 2.! At! each! stage,! aliquots! of! all!




Ctag6LV! and! (b)! viral! titres! of! all! fractions! are! plotted! with! values! representing!









In! the! previous! experiment,! we! demonstrated! complete! capture! of! LVs! by!










reduction,! with! less! than! 8! ±0.1! x103! IU/mL! left! in! the! flow6through.! This!









120!minutes! at! both! temperatures,! the! latter! did! appear! to! result! in! higher!
captured! viral! titre.! However! due! to! practical! reasons! as! well! as! lack! of!
statistical! significance,! incubation! of! 60! minutes! was! chosen! as! standard!
incubation! for! any! following! capture.! Therefore,! for! all! subsequent!

















titre! for! (a),!and!percentage!of!neat!viral! titres! for! (b)!±!standard!deviation! (SD)!of!






process! can! completely! capture! infectious! particles! independently! of!
pseudotyping!glycoprotein!envelope.!Since!Ctag!modification!of!LVs!occurs!
through!random!incorporation!of!the!peptide,!pseudotyping!viral!particles!with!
any! envelope! should! allow! the! complete! capture! of! modified! particles.! To!
demonstrate!this,!LV!stocks!were!produced!from!both!NT6!and!Ctag6293T!cells!
pseudotyped!with!RDpro,!MLV6A!and!VSV6g! in! serum6free!media.!NM!and!
Ctag6LV! stocks! of! each! glycoproteins! were! then! titred! on! NT6293T! cells!
(Figure!4.9a6b).!There!was!no!significant!difference!in!viral!titres!between!NM!
and!Ctag6LVs!produced!for!each!of!the!three!glycoproteins,!with!the!highest!
titres! of! 107! IU/mL! for! VSV6g! pseudotyped! vectors.! Next,! tagged! and! non6






temperature.! Then,! after! flow6through! fractions! separation,! infectious! titres!
were!determined!for!all!fractions!and!plotted!as!a!percentage!of!neat!viral!titres!
(Figure! 4.9c).! As! expected,! Ctag6LV! pseudotyped!with!RDpro,!MLV6A! and!
VSV6g! were! successfully! captured! by! streptavidin! beads! as! indicated! by!
increased!viral!titres!of!all!bead!fractions,!with!2.8,!3.5!and!2.26fold!higher!viral!
titres! compared! to! neat! fractions! for! RDpro,! MLV6A! and! VSV6g! LVs,!
respectively! (Figure!4.9c).!These! results!validated! the! independency!of!our!
purification!methodology!from!viral!pseudotyping!glycoproteins.!!
%
Figure% 4.9:% Application% of% developed% streptavidin=mediated% capture% protocol%




grouped! columns! in! (a)! and! corresponding! values! in! table! (b)! with! ±! standard!
deviations!(SD)!of!triplicate!determinations.!(c)%RDpro,!MLV6A!and!VSV6g!NM6!and!
Ctag6LVs!were!subjected!to!capture!protocol!using!optimized!conditions.!Neat,!beads!


















were!performed! for!1!hour!at! room! temperature.!Then,!after!PBS!washing,!
RDpro!pseudotyped!NM6!and!Ctag6LVs!were!incubated!with!both!pre6treated!
beads! for! 1! hour! at! room! temperature.! After! flow6through! separations,!
infectious! titres!were!determined!for!all! fractions!by! infectivity!assay!(Figure!
4.10a6b).!Consistently,!Dynabeads!pre6incubated!with!PBS!only,! resulted! in!
significant! 56fold! increase! in! viral! titre! of! captured! Ctag6LV! compared! to!
starting! material,! and! only! 17! ±2%! of! titre! remaining! in! flow6through.! As!
anticipated,! pre6incubation! of! streptavidin! Dynabeads! with! 15mM! biotin!
blocked!Ctag6LV!binding! resulted! in! lack!of!capture,!with!100%!of!Ctag6LV!
found! in! the! flow6through! fraction.! Accordingly,! an! increased! statistical!
difference!was!observed!between!viral!titres!of!PBS6!and!biotin!pre6incubated!













viral! titres!were! determined! by! infectivity! assay.% (a)%Dot! plots! of! eGFP! vs!SSC6A!
represent!cells!transduced!with!250μL!of!all! fractions!for!both!NM6LV!and!Ctag6LV!
without!any!volume!reduction.%(b)%Viral! titres!of!all! fractions!are!plotted!with!values!










cells! expressing! the! mimic! on! their! surfaces.! This! modification! permitted!
subsequent!streptavidin!magnetic!beads!capture!of!all!infectious!RDpro,!VSV6
g!and!MLV!pseudotyped!Ctag6LVs!in!an!epitope6dependent!manner.!!
Initially! different! methods! of! viral! surface! incorporation! were! tested! in! this!
Chapter.! First,! we! constructed! a! chimeric! protein! consisting! of! Ctag6CD8α!












to! produce! detectable! infectious! viral! particles.! Peptide! engineering! on!
RDpro’s!SU!may!have!inhibited!its!receptor!binding!domain!on!target!cells.!On!
the! other! hand,! peptide! incorporation! on! its! TM! domain! may! hindered! its!
required!conformational!change!for!fusion!activity.!Both!of!these!possibilities!
would! be! in! line! with! the! generally! accepted! limitations! of! envelope!
glycoprotein!engineering!(Buchholz!et!al.,!2015b!Friedel!et!al.,!2015b!Lévy!et!
al.,!2015).!Failure!to!detect!infectious!particles!may!also!have!been!caused!by!
insufficient! surface! expression! of! engineered! glycoproteins! required! for!
efficient!pseudotyping!of!LVs.!This!could!have!been!assessed!by!staining!for!
RDpro!alongside!biotin!mimic.!However,!this!was!not!possible!due!to!the!lack!





ELISA! may! have! also! helped! to! determine! whether! the! lack! of! infectious!
particles!was!caused!by!hindrance!of!envelope!functionality!for!infection!(both!
its! receptor! binding! and! fusogenic! function)! or! insufficient! membrane!
expression,!had!caused!the!lack!of!infection!observed!with!both!engineered!
variants!of!RDpro.!Nonetheless,!these!results!indicate!the!difficulty!faced!when!
attempting! to! genetically! engineer! envelope! glycoproteins! with! intertwined!
receptor!binding!and!fusion!domains.!!
Finally,! as! a! third! strategy! for! viral! modification,! we! tested! the! random!
incorporation! of! Ctag! by! genetically! engineered! packaging! cells.! There! is!
sufficient! evidence! to! suggest! that! proteins! expressed! on! vector! producing!
cells! could! get! incorporated! on! budding! virions’! surfaces.! LVs! have! been!
reported!to!assemble!at!lipid!rafts,!and!as!a!consequence!GPI!proteins!residing!








Garoff! (2004).! Ctag’s! passive! inclusion! is,! as! expected,! independent! of!
pseudotyping! glycoproteins,! as! indicated! with! complete! streptavidin! bead!
capture! of! both! VSV6g! and!MLV6A! pseudotyped! vectors.! Moreover,! vector!
infectivity! does! not! seem! to! be! affected! by! Ctag’s! modification,! as! no!
significant!difference!was!observed!between!modified!and!non6modified!LVs.!
Therefore,! given! its! inertness! on! viral! function,! the! genetic! engineering! of!
vector!producing!cells!with!a!surface!protein,!such!as!Ctag,! is!an!attractive!







acquired! upon! budding! from! vector! producing! cells,! was! sufficient! to! bind!





vectors! bound! to! streptavidin! Dynabeads! was! observed,! without! volume!
reduction.! This! observation! of! increased! viral! titres! from! modified! vectors!
bound!to!magnetic!particles!has!been!previously!documented!(Hughes!et!al.,!
2001b!Scherer!et!al.,!2002b!Nesbeth!et!al.,!2006),!with!significantly!higher!fold!
increases! in! viral! titres,! indicating! an! enhancement! in! infection! rates! with!
vectors!bound!to!larger!particles.!This!phenomenon!could!be!explained!by!the!
difference! in! the! number! of! vectors! exposed! to! target! cells! between! those!
bound!to! large!particles!compared!to! those! in!harvested!viral!supernatants.!
Due! to! the! higher! gravitational! pull! of! 1µm!magnetic!particles! compared! to!
diffusion! rates! of! free6floating! vectors,! a! higher! number! of! infectious! viral!
particles! would! come! into! close! proximity! to! target! cells,! thus! resulting! in!
increased!transduction!efficiencies,!without!any!volume!reduction.!!
In! this!Chapter,!LVs!surfaces!were!modified! to!express! the!synthetic!biotin!
mimic,!Ctag!by!its!random!incorporation!during!virion!budding.!The!density!of!
Ctag!on!viral!particles!was!sufficient!to!allow!their!complete!capture!from!viral!
supernatant! by! streptavidin! magnetic! beads! in! a! one6step! protocol,! also!




streptavidin! beads.! We! therefore! reasoned! that,! with! orders! of! magnitude!
higher! binding! affinity! to! streptavidin,! the! introduction! of! biotin! should!








In! the! previous!Chapters,! LVs!were!modified!with!Ctag! biotin!mimic!which!
allowed!their!successful!capture!by!streptavidin!from!surrounding!clarified!viral!
supernatant.!As!the!affinity!of!this!peptide!to!streptavidin!(KD!230nM)!is!orders!




The! extraordinary! strength! of! the! biotin! 6! streptavidin! bond! comes! at! the!
expense!of!its!fundamentally!irreversible!binding!for!biotinylated!target!protein!
elution.!However,!recovery!of!captured!targets!is!essential!for!any!purification!
method.! In! response! to! this!major! challenge,! several! different! approaches!
have!been!developed!and!employed!to! induce!reversible!binding!of! targets.!




urea! and! thiourea! and! involving! an! incubation! step! at! 96°C! (Rybak! et! al.,!
2004).! Alternatively,! biotin! derivatives! with! reduced! affinities! such! as!
iminobiotin!can!be!used,!which!binds! in!a!pH6dependent!manner!binding!at!
pH11! and! dissociating! at! pH4! (Hofmann! et! al.,! 1980).! Also,! chemically!
modified!molecules!can!be!utilised!such!as!photocleavable!biotin!which!results!
in! streptavidin! bond! cleavage! by! light! (Olejnik! et! al.,! 1995).! Otherwise,!
streptavidin!binding!site!can!be!engineered!to!reduce!binding!affinity!to!biotin!










but!may!not!be!applied! for! the!purification!of! labile!complexes!such!as!viral!
vectors!all!the!while!retaining!their!infectivity.!!
5.2.1% Elution%of%biotinylated%viral%vectors%%
Due! to! the! remarkable! specificity! of! biotin6streptavidin! interaction! and! its!
potential,!a!handful!of!studies!have! reported! the!capture!and!purification!of!
biotinylated!viral!vectors!from!(strept)avidin!matrices.!As!a!benchmark,!the!field!
attempted! to! apply! elution! conditions! optimized! for! biotinylated! protein!
recoveries,! on! viral! vector! purification.! However,! as! mentioned,! almost! all!
elution! methods! for! the! recovery! of! biotinylated! proteins! relied! on! harsh!
conditions.! Accordingly,! Williams! et! al.! (2005)! tested! different! desorption!
agents! such! as! urea! and! guanidine6HCL! for! elution! of! streptavidin6bound!
biotinylated!viral!vectors!and!resulted! in!vector! inactivation.!Conversely,! the!
use! of! 0.6mM! biotin! as! specific! desorption! agent! for! vectors! bound! to!
streptavidin!Fractogel®!polymeric!beads,! resulted! in!a! low!yield!of!5%. This!
highlight!the!inefficiency!of!biotin!displacement!by!free!biotin!in!excess!owing!
its!low!dissociation!constant!(KD!10615!M).!Low!recoveries!were!also!reported!





proteins.! Although! only! 52%! of! desthiobiotinylated6LVs! captured! by!
streptavidin!Magnesphere®,!elution!with!2mM!biotin!resulted!in!68%!of!bound!
vector! recovery,!making!an!overall! yield!of!35%!of!purified!LVs.!Therefore,!
even! though! biotin6mediated! elution! of! desthiobiotinylated! vectors! was!
efficient,! its! viral! vector! metabolic! modification! required! (i)! exogenous!








The! development! of! biotin! mimicking! peptides! has! allowed! for! specific!
purification!by!competitive!elution! resulting! in! target!elution! from!resin.!This!
process! is! very! attractive! for! labile! complexes,! such!as!LV!particles,! it! is! a!
passive!process!that!only!requires!first!the!dissociation!of!complex!to!allow!a!
competitor,!with!a!higher!on6rate,!to!bind!and!result!in!displacement!of!bound!
targets.! Moreover,! currently! used! active! elution! of! different! affinity!
chromatography!may!be!regarded!as!inferior!compared!to!competitive!elution,!
as!they!consist!on!changing!overall!buffer!composition.!This!in!turn!alters!the!
nature! of! interacting! molecules! causing! the! release! of! purified! target! for!
example!by!pH!shifting.!Therefore,!as!an!elution!strategy,!competition!binding!
provides!key!advantages!over!other!currently!used!active!elution!processes,!
in! that! it! is!milder!and!confers!a!second!specificity!step,!as!only!selectively!
captured!targets!are!displaced!from!binding!pockets.!!
5.2.2.2% Elution%of%recombinant%proteins%engineered%with%biotin%mimics%%




of! target!bait!proteins!and! their! subsequent! recovery!by!competitive!elution!


















aimed! at! analysing! interacting! partners! of! engineered! targets! by! mass!
spectrometry! (MS),! the! addition! of! denaturing! agent! in! elution! buffer! was!
possible.!This!would!not!be!the!case!for!the!elution!of!captured!viral!vectors!as!
retaining! infectivity! in! overall! eluted! yield! is! a! prerequisite! for! any! viral!
purification!method.!
5.2.2.2.2!Strep6tag!
The! Strep6tag®! peptides! have! been! widely! used! for! various! applications!
ranging! from! purification! of! recombinant! proteins! such! as! metalloenzyme!
proteins! (Maier! et! al.,! 1998)! and! phosphatases! (Junttila! et! al.,! 2005b)! and!
multimerisation! of! MHC! molecules! (Knabel! et! al.,! 2002).! Additionally,!
Streptag®!have!been!used!in!several!tandem!affinity!purifications!with!hexa6
histidine! (Cass! et! al.,! 2005b! Locatelli6Hoops! and! Yeliseev,! 2014).! The!
streptavidin!mutant!StrepTactin!immobilised!on!sepharose!resin!was!used!for!
target! capture! for! all! Strep6tag®! purification.! Moreover,! Streptag6III! (or!
commercially!known!as!Twin6Strep6Tag!from!IBA),!containing!two!versions!of!
Streptag6II! separated!by!a! linker,!has!been!shown! to!exhibit!higher!binding!
kinetics! to! StrepTactin! compared! to! Strep6tag6IIb! and! is! currently!
manufacturer’s! recommended! Streptag®! for! target! affinity! purification!
(Schmidt! et! al.,! 2013).! The! analogue! desthiobiotin! is! the! recommended!
desorption!agent!for!the!elution!of!Streptag®!fused!protein!from!StrepTactin!
resin.! StrepTactin! resin! can! then! be! regenerated! by! applying! the! azo! dye!










However,! desthiobiotin6mediated!displacement! has! faced! certain! limitations!
for! competitive! overall! yields.! Purification! of! plant6derived! Streptag6II! fused!
kinases! from!StrepTactin! resin!using!10mM!desthiobiotin!was!unsuccessful!
and!required!SDS6containing!elution!solution!(Witte!et!al!2004).!This!was!later!





shown! to! cause! undesirable! sample! contamination! with! StrepTactin!
monomers! released! from! resin.! Authors! circumvented! this! problem! by! first!
chemically! cross6linking! monomers! using! BS3!
(bis(sulfosuccinimidyl)suberate),!then!eluting!Streptag6III!fused!target!protein!
and!its!associated!interacting!proteins!with!denaturing!elution!buffer!containing!

















vectors! and! streptavidin! allowed! the! compete! capture! of! viral! titre! using!
streptavidin!conjugated!magnetic!beads.!As!mentioned!above,!a!pre6requisite!
for!any!viral!purification!method! is! the! release!of!purified! infectious!vectors!
from!resin!with!high!purity!and!yield.!We!have!previously!demonstrated!that!(i)!
Cell! membrane! expressed! Ctag’s! binding! to! streptavidin! was! displaced! by!




•! Testing! and! developing! the! elution! of! Ctag6LV! bound! to! streptavidin!
beads!resulting!in!competitive!overall!yields.!
•! Assessing!biotin!mediated!toxicity!on!infectious!Ctag6LVs.!!













As! this! project! aimed!at! developing!a! one6step! vector! purification! protocol,!
subsequent! elution! of! captured! vectors! from! beads! is! desirable.! Since! the!
displacement! of! Ctag! bound! to! streptavidin! by! biotin! has! been! previously!
demonstrated!(Chapter!3),!the!recovery!of!Ctag6LV!from!streptavidin!magnetic!
beads! by! biotin! was! tested.! To! that! end,! Ctag6LVs! were! captured! by!
streptavidin!beads!as!per!Methodology!2%(Section!4.8).!The!beads!were!then!
incubated!with!DMEM!supplemented!with!a!saturating!concentration!of!biotin!
at! 30mM,! for! 2! hours! at! 4°C! (Figure! 5.1).! Subsequently,! fractions! were!
separated!into!eluate!(collected!after!bead!magnetization!containing!displaced!
Ctag6LV)!and!beads!eluate!(containing!beads!post6eluate!collection)!to!assess!






of! bound! vector! (6.2! ±1.0! x104! IU/mL),! which! represented! 24%! of! starting!
vector!particles.!However,!17%!of!Ctag6LV!neat!particles!were! found! in! the!
bead! eluate! fraction! (4.3! ±4.0! x104! IU/mL),! indicating! the! incomplete!
displacement!of!Ctag6LV!by!biotin.!Given!the!significantly!lower!affinity!of!Ctag!
compared! to! biotin! for! streptavidin! (Giebel! et! al.,! 1995),! the! saturating!
concentration! of! 30mM! biotin! should! allow! the! dissociation! of! all! Ctag6LV!
bound!to!streptavidin!magnetic!beads.!The!inconsistency!in!the!overall!yields!
of!beads!eluate!in!the!three!experiments!performed!should!be,!as!irrespective!



































overall! yields! between! glass! (19%)! and! polypropylene! containers! (15%)b!














Thus! far,!elution!experiments,!which! require! the!out6competition!of!Ctag!by!
biotin!from!streptavidin!binding!pocket,!were!performed!in!plain!DMEM.!This!
basal!medium!contains!no!growth!promoting!agents!or!proteins.!Therefore,!an!
alternative!hypothesis! for!the! loss!of! infectivity!was!postulated! that!DMEM’s!
relative! lack! of! protein! supplements! may! have! caused! aggregation! and/or!
inactivation!of!labile!RDpro!pseudotyped!LVs.!It!should!be!mentioned!that!this!
phenomenon! might! have! occurred! in! the! bead! captured! fraction! but! was!
undetected! due! to! the! increased! viral! titre! achieved! with! vector! bound! to!
magnetic! particles.! It! should! also! be! noted! that! since! we! only! focused! on!
infectivity! assessment! of! recovered! vectors,! physical! particles! were! not!
investigated.!Nevertheless,!we!first!decided!to!test!elution!of!captured!Ctag6
LV!in!the!presence!of!fetal!calf!serum!(FCS),!dialyzed!to!remove!biotin!(dFCS).!













of! vector! captured! beads! with! 15mM! biotin,! resulted! in! an! undetectable!


































53%! of! VSV6g! Ctag6LV! titre! was! captured! by! streptavidin! beads.! This! low!
percentage! of! capture! was! only! observed! in! this! experiment! as! almost!
complete! capture! of! VSV6g! pseudotyped! Ctag6LV! has! already! been!































biotin! incubation! and! 2.05! x105! and! 3.58! x104! IU/mL! after! plain! media!





IU/mL!was!captured,!with! increased! infectivity!of!5.44!x104! IU/mL,!and!then!
subjected!to!incubation!with!biotin!titration!from!15mM!to!468.75µM!in!DMEM!
supplemented! with! 5%! dFCS,! for! 2! hours! at! 4°C.! Eluate! fractions! were!








chemically! defined,! serum6free!medium,! X6vivoTM!was! tested! as! an!elution!
solution!alongside!DMEM.!Unlike!the!latter,!X6vivoTM!contains!proteins!and!has!







with! 500µM! biotin! was! supplied!with! either! 0.1%! or! 0.5%! of! BSA! or! HAS,!
separately.!In!this!experiment,!high!titre!fresh!Ctag6LV!viral!supernatant!was!
produced! (2.5! x105! IU/mL)! for! elution! testing! and! was! thus! subjected! to!
streptavidin!magnetic!beads!capture,! resulting! in!2.26fold!higher!viral! titre!of!
5.34! x105! IU/mL.! Subsequently,! captured! Ctag6LV! was! incubated! with! the!
different!conditions!shown!in!Figure!5.4d!for!2!hours!at!4°C.!Eluates!fractions!





IU/mL)! of! viral! particles,! whereas! the! addition! of! 500µM! biotin! to! X6vivoTM!





0.5%! BSA! resulted! in! the! highest! overall! elution! yield! from! streptavidin!






Figure% 5.4:%Optimization% of% viral% recovery% and% elution% buffer% formulation.% (a)!
Large!batch!of!fresh!NM6LV!(2.05!x105!IU/mL)!and!Ctag6LV!(3.58!x104!IU/mL)!vectors!
were!produced!and!viral! loss!due!to!one!cycle!of! freeze6thawing!(F6T)!of! the!stock!
was!determined!by!comparing!it!to!fresh!viral!supernatant.!(b)!Viral!titres!of!both!NM6!




in!DMEM!of! 1:2!dilutions! for! 2!hours!at!4°C.! (d)!Ctag6LV! recovery!efficiency! from!
Dynabeads!was! tested! in!either!DMEM!or!X6vivoTM615! in!different! formulations! for!






containing! elution! buffer,! was! demonstrated! to! result! in! increased! viral!
recoveries.!However,!elution!recovery!appeared!to!be!saturated!with!a!wide!





from! stock! (1.2! ±0.11! x105! IU/mL)! was! captured! by! streptavidin! magnetic!
beads,!and!subsequent!bead!fraction!(1.9!±0.09!x105!IU/mL),!was!incubated!






150µM! and! 1.5µM! biotin,! respectively.! Crossing! into! the! nanomolar!
concentration! of! biotin,! starting! from! 15nM,! 150pM,! 1.5pM! and! 15fM,!
significantly!reduced!the!displacement!efficiency!of!bound!vectors!to!3%!+/6!1,!
2.3! ±0.5%,! 1.3! ±0.5%! and! 1%,! respectively.! These! results! indicate! that!
increasing!the!number!of!biotin!molecules!by!1006fold!did!not!seem!to!relatively!
increase! displacement! efficiency.! Moreover,! although! we! could! not! have!
achieved!a!dose6dependent!elution!with!recoveries!higher!than!30%,!the!EC50!
was! determined! at! 208nM! biotin,! which! is! the! required! concentration! to!
displace!50%!of!maximal! recovery!of!30%.! In!addition,! the!sigmoidal!graph!
generated!a!Hill!slope!of!1.089,!indicating!that!biotin!may!be!competing!with!
multiple! binding! sites! on! Ctag6LV,! which! may! explain! the! incomplete!
dissociation!of!captured!vectors.!Taking!into!consideration!the!number!of!biotin!
molecules!in!these!concentrations,!a!significant!amount!of!biotin!seemed!to!be!
required! for! the! competitive! elution! of! a! portion! of! bound! Ctag6LVs.! More!
specifically,! a! 208nM! concentration! of! biotin! in! the! volume! used! (0.5mL)!
contained! 6.26! x1013! number! of! biotin! molecules.! This! concentration!
successfully!out6competed!15%!of!neat!Ctag6LV!which!contained!1.86!x104!


















fractions! were! collected! and! assayed! for! viral! infectivity! and! values! ±! standard!
deviation! (SD)! of! triplicate! determinations! are! presented.% (b)! Dose6dependent!
displacement!graph!of!percentage!of!Ctag6LV!recovered! in! the!different! relative! to!









consecutive! displacement! of! Ctag6LV! by! sequential! exposure! to! biotin! of!
beads! eluate! (containing! non6displaced! Ctag6LV).! In! addition,! in! this!
experiment!we!aimed!to!analyze!eluted!Ctag6LV!by!Malvern’s!Nanosight!that!




nanoparticles! from! 1062000nm.! This! analysis! relies! on! the! tracking! of!
nanoparticles! and! requires! particles! resuspension! in! solution! with! velocity!
coefficient! of! 1.! Therefore,! for! the! purpose!of! Nanosight! analysis,! Ctag6LV!












then!beads!eluate!were! re6incubated!with!150X!elution!buffer! for! two!more!
rounds!of!elution! incubations.!Individual!viral! recoveries!of!collected!eluates!
(150X)!were!determined!and!samples!were!then!pooled!together!into!a!50X!




biotin! concentration.! Second! incubation! of! beads! eluate! with! fresh! elution!
buffer!(E2)!resulted!in!the!recovery!of!6!±0.5%!of!Ctag6LV,!with!8!±0.036fold!













fraction! was! incubated! again! with! the! elution! buffer! at! the! same! conditions! for! a!
second! (E2)!and!a! subsequent! third! (E3)! time.!Each!eluate!was!sampled! for! viral!
titration!at!150X!volume!concentration!and!then!pooled!together!(E6ALL)!with!a!final!
50X!volume!concentration!compared!to!neat.!(a)%Viral!titres!of!all!collected!fractions!
and! (b)! overall! viral! yield! of! eluates! ±! standard! deviation! (SD)! of! triplicate!
determinations!are!presented.!(c)!Nanoparticle!tracking!analysis!for!E6ALL!product!
characterization!by!Nanosight!technology!which!records!five!separate!video!analysis!
of! samples! to! determine! its! overall! concentration! in! particles/mL.! (d)! Image!
representing! screenshot! of! one! of! the! captured! videos! for! visualization! of! E6ALL!
particle!composition.!!
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of! biotin6mediated! competitive! elution! without! the! knowledge! of! how!many!




rates.! In! an! attempt! to! both! characterize! and! quantify! the! number! of! Ctag!
molecules!per!LV!particles,!all!three!eluate!fractions!where!pooled!together!(E6
ALL)b!resulting!in!a!viral!titre!that!was!14!±0.486fold!higher!than!neat,!with!8.61!




allowing! the! possibility! of! staining!Ctag6LVs!with! streptavidin! conjugated! to!
FITC,!in!order!to!attempt!the!quantification!of!biotin!mimic!per!particle.!NTA!
analysis! of! frozen6thawed! eluted! Ctag6LV! (50X)! vectors! by! Malvern’s!
Nanosight! resulted! in! the! characterization! of! two! distinct! particle! size!
populations! as! indicated! by! the! two! peaks! of! the! five6separate! analysis!
summarized! in! Figure! 5.6c.! Accordingly,! both! small! particles! and! large!
aggregates!can!be!visually!seen!in!Figure!5.6d,!which!represents!an!image!of!
one! of! the! videos! acquired! by! the! NTA! software.! Consequently,! size!
distribution!analysis!determined!a!mean!size!of!180!±3.0!nm,!with!a!mode!of!
151!±6.9nm,!which!are!larger!than!the!accepted!size!of!LVs!of!~!120nm.!Given!
the! lack! of! single! size! nanoparticle! detection,! any! characterization! of!Ctag6
LVs,! such! as! concentration! of! particle/mL,! would! not! have! been! accurate.!
Moreover,! fluorescent! staining! of! Ctag6LV! had! failed,! not! allowing! the!














binding! site! due! to! aggregation! or!molecular! crowding.! The! latter! scenario!
unfortunately!was!not!tested!in!the!experimental!scope!of!this!project!due!to!
the! difficulty! in! assessing! both! particle! composition! and! interaction! on! a!
nanometer!scale.!Nonetheless!the!former!possibility!was!tested!by!indirectly!
altering! the! expression! of! Ctag! on! viral! particles! and! evaluating! whether!
altered!vector!avidity!can! lead! to! increase!viral! recoveries! from!streptavidin!
magnetic! beads! by! excess! biotin.! Since! LVs! acquire! Ctag! molecules! by!
passive!incorporation!while!budding!from!vector!producing!cells,!we!reasoned!
that!altering!the!density!of!Ctag!on!these!cells!should!in!turn!alter!its!density!






















supernatants! were! then! subjected! to! purification! by! incubation! with!
streptavidin!beads.!Elution!was!then!performed!by!bead!fractions!incubation!
with! X6vivoTM! containing! 500µM! biotin! and! 0.5%!BSA,! without! any! volume!
reduction.!As! in!previous!experiments,!all! fractions!were!collected!and!their!
viral!loads!determined!by!infectivity!assay!(Figure!5.8).!In!this!experiment,!the!
effect! of! differential! Ctag! expression! on! LV! particles! was! tested! for! both!
streptavidin! capture! and! biotin! mediated! elution! efficiencies.! Starting! with!
capture,!a!significant!difference!was!observed!between!viral!titres!of!neat!(2.5!




produced! only! from! Ctag6low! 293T! cells.! This! indicated! that! passive!
incorporation!of!Ctag’s!density! from! low!expressing!cells!onto!viral!particles!
was! not! sufficient! for! complete! viral! particle! capture! (Figure! 5.8a).! No!
significant!difference!was!observed!between!neat!viral! titres!produced!from!
both! medium6! (1.44! ±0.11! x105! IU/mL)! and! high6! (1.88! ±0.26! x105! IU/mL)!
expressers!compared!to!their!bead6captured!fractions,!with!viral!titres!of!1.8!
±0.56! x105! and!2.55! ±0.53! x105! IU/mL,! respectively.! Taken! together! these!
results!implied!that!a!minimum!density!of!Ctag!on!LVs!surfaces!seemed!to!be!
required! for! significant! vector! capture! by! streptavidin! magnetic! beads.!
Accordingly,!using!Pearson!product6moment!correlation!coefficient,!a!positive!
correlation! was! detected! between! Ctag’s! MFI! on! 293T! cells! and! capture!




to!Ctag6L!LVs!(Figure!5.8c).!This! further! indicates! that!an!expression!of! the!






Figure% 5.8:% Capture% and% displacement% efficiency% with% differential% Ctag%
expression%of%LVs.%LVs!were!produced!from!low!(L),!medium!(M)!and!high!(H)!Ctag6
expressing!293T!cells!by!transient!transfection.!VCMs!were!then!subjected!to!capture!
of! developed!methodology! by! streptavidin!Dynabeads.!Beads! fractions!were! then!
incubated!with!X6vivoTM615!elution!buffer!containing!500µM!biotin!and!0.5%!BSA!for!






presented!with!±!standard!deviation! (SD)!of! three! independent!experiments! (n=3),!
with! ns! p! ≥! 0.05,! *! p! ≤! 0.05,! **! p! ≤! 0.01! and! ***! p! ≤! 0.001.! R2! as! coefficient! of!
determination.!
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using!X6vivoTM! supplemented!with! 500µM!biotin! and!0.5%!BSA! resulted! in!
recoveries!of!32!±7.8%,!39!±7.0%!and!52!±2.5%,!for!low,!medium!and!high!














In! this! experiment,! X6vivoTM,! DMEM! and! OptiMEM! were! tested! as! elution!
buffers,!either!plain!or!supplemented!with!500µM!biotin!and!0.5%!BSA!(Figure!
5.9).!Both!NM6LV!(4.48!±0.25!x104!IU/mL)!and!Ctag6LV!(4.3!±0.5!x104!IU/mL)!
viral! supernatants! were! subjected! to! streptavidin! bead! capturing! as! per!
optimized! methodology,! for! 1! hour! at! room! temperature.! Consistently,!
magnetic!bead!capture!of!Ctag6LV!resulted!in!a!36fold!increased!viral!titre!of!
1.6! ±0.14! x! 105! IU/mL! (Figure! 5.9a).! Unlike! previous! experiments,! elution!
incubations!were! performed!at! room! temperature! for! 1! hour,!which! lead! to!
higher!elution!recoveries!of!67%!±5.6,!58%!±8%!and!59%!±9!using!X6vivoTM,!
DMEM!and!OptiMEM,!respectively!(Figure!5.9b).!The!presence!of!BSA!in!the!
















bead! fraction! was! then! subjected! to! elution! in! three! different! media:! X6vivoTM615,!
DMEM!and!OptiMEM,!each!supplemented!with!plain,!500µM!biotin!and!500µM!biotin!
with!0.5%!BSA.!(b)!Viral!recoveries!of!different!conditions!were!determined.!All!values!





incorporation! of! Ctag! onto! their! viral! surfaces.! It! has! been! shown! that! the!
density! of! Ctag! on! LV! particles! can! impact! both! vector! capturing! by!
streptavidin,! and! its! subsequent! elution! by! biotin.! However,! without!
determining! the!number!of!Ctag!molecules!on! the!surface!of!viral!particles,!
overall! avidity! of!modified! vectors! for! streptavidin! may! represent! a! limiting!
factor! for! improved! elution! rates.! Moreover,! identifying! Ctag’s! density! per!
particle!may!help!understand!the!underlying!molecular!mechanisms!of!capture!
of! vector! by! magnetic! beads,! in! terms! of! mechanical! interactions! of! two!














It! is! common! practice! to! quantify! antibodies! bound! per! cell! (ABCs)! to!











modified! LVs,! the! biotin! mimic’s! surface! density! on! these! cells! was!
investigated.! Cells! were! therefore! harvested! and! stained! with! streptavidin!
conjugated!to!PE!and!expression!was!determined!by!flow!cytometry!along!with!











tetramer! we! have! reasoned! that! a! maximum! of! two! binding! sites! on!
streptavidin!can!be!occupied!by!Ctag!peptides!expressed!on! the!surface!of!
cells!at!a!given! time,! thus!making! the! ratio!of!1:2! for!PE:Ctag6binding!sites!




these!particles! acquire! the! cells’! lipid! bilayer.! Therefore,!assuming! that! the!
diameter!of!a!293T!cell!is!15µm!and!that!of!LV!is!120nm,!then!the!surface!of!
cells! is! 15639! times! larger! than! the! surface! of! a! viral! particle.! Taking! into!
account! the!estimated!number!of!Ctag!molecules!on! the!surface!of!Ctag6H!
293T! cells,! each!modified!Ctag6LV! particle!would! by! extrapolation! express!
around!3!copies!of!Ctag!peptides!on!its!surface!(Figure!5.10c).!It!should!be!
noted! that! this! number! is! based!on! the! assumption! that!Ctag’s!density!per!
cells’!surface!per!µm2!is!equivalent!to!that!on!viral!surface!per!µm2.!And!thus,!
this!result!does!not!represent!a!quantitative!analysis!of!a!mimic’s!density!on!








and! Ctag6High! 293T! cells! stained! with! streptavidin! conjugated! to! PE.! (b)!
Histogram! of! flow! cytometry! acquisition! of! QuantiBRITE6PE! beads! with!
defined! four! populations.! Their! respective! quantitative! geometric! means!
(Log10! of! their! geometric! means)! were! plotted! against! Log! 10! of! known!
amount!PE!molecules! per! bead! for! a! linear! regression!analysis!with!R2! as!










on! the! surface! of! samples! and! their! compositions.! Moreover,! streptavidin!
conjugated!to!gold!particle!can!be!used!to!detect!Ctag!molecules!on!modified!








detection! using! SEM,! both! NM6! and! Ctag6LV! stocks! were! purified! by!
ultracentrifugation! on! a! 20%! sucrose! cushion! and! concentrated! 100X! in!
OptiMEM.!First,!control!and!modified!LVs!were!pseudotyped!with!RDpro!and!
sucrose!purified!vectors!resulted!in!a!236fold!increase!in!viral!titres!for!both!NM!
and! Ctag6LVs,! with! 2.54! ±6.18x106! IU/mL! and! 1.26! ±0.62! x106! IU/mL,!
respectively! (Figure! 5.11a).! However,! it! was! then! decided! to! use! VSV6g!
pseudotyped! LVs! due! to! its! relative! stability! to! freeze6thaw! cycles! and!
increased! viral! titres! compared! to! RDpro.! Correspondingly,! purification! of!
VSV6g!pseudotyped!vectors!resulted!in!18!and!276fold!increases!in!viral!titres!
for! NM6! and! Ctag6LVs! with! 3.97! ±0.37! x107! and! 6.87! ±0.36! x107! IU/mL,!
respectively.!Next,!the!binding!of!thawed!purified!VSV6g!vectors!to!streptavidin!
magnetic! beads! was! demonstrated! before! staining! with! gold6labeled!
streptavidin! (Figure! 5.11b).! Subsequently,! samples! were! processed! for!










in! OptiMEM! resulted! in! the! visual! determination! of! intact! viral! particles.!
Subsequently,! thawed! samples! were! then! stained! with! streptavidin6gold!
particles!prior!of!negative!staining!for!SEM!for!1!hours!at!room!temperature!
with! gentle! shacking! to! keep! mixture! in! suspension! (Figure! 5.11d).! As!
expected,!whole!particles!were!observed!by!SEM!for!both!samples.!Moreover,!
unlike!NM6LV,!3!streptavidin!gold!particles!were!detected!by!naked!eye,!lying!
in! close! proximity! to! Ctag6LV! viral! particle.!However,! due! to! the! significant!
background!binding!of!streptavidin6gold!observed,!the!former!observation!was!


























In! this! Chapter,! we! have! demonstrated! efficient! displacement! of! bead6
captured!Ctag6LV!by!competitive!elution!using!free!biotin,!resulting!in!recovery!
of!≥!60%.!This!required! the!presence!of!protein!additives!such!as!BSA!and!
can! be! achieved! using! different! cell! culture! formulations.! We! have! also!
demonstrated! that! passive! Ctag! incorporation! does! not! alter! physical!
morphology! of! vectors! allowing! wide! applications! of! this! developed!
purification.! It! should! be! mentioned! that! to! the! best! of! our! knowledge,!
purification!of!any!viral! vector!using!a!biotin!mimic!and! its!natural! receptor,!
albeit!it!avidin!or!streptavidin,!has!not!been!reported!yet.!Therefore,!no!body!
of! work! in! the! literature! exists! to! compare! this! chapter’s! results.! Elution! of!
metabolically! biotinylated! AAV! from! monomeric! avidin! has! been! reported!
(Parrott! et! al.,! 2000).! However,! given! the! differences! in! their! physical!
properties!and!levels!of!fragility,!purification!methodologies!between!AAV!and!
LVs!cannot!be!readily!interchanged.!!
A!major! limitation! in! the!early!elution!experiments!preformed! in! this!chapter!
was! the! quantification! of! only! infectious! particles! after! elution! and! not! of!
physical!particles.!The!effect!of!bead6bound!vectors!resuspension! in!elution!
buffers!on!physical!particles!should!have!been!determined!by!quantifying!total!
physical! particles.! This! in! turn! limited! the! investigation! into! the! loss! of! titre!
observed!in!elution!experiments!performed!in!plain!media!supplemented!with!
high! concentration! of! biotin.! Nonetheless,! as! the! ultimate! aim! of! our!
methodology! was! the! purification! of! infectious! LVs,! assessing! infectivity! of!
overall!yield!was!our!main!end!point!during!the!development!of!this!desorption.!
It!was!postulated!that!excess!concentrations!of!biotin!may!have!caused!some!




observed! with! the! addition! of! up! to! 15mM! biotin! in! plain! DMEM,! on! both!






Alternatively,% this! loss% may! have! been! caused! by! viral! aggregation.! The!
presence!of!viral!aggregates! is!a!common!product6related! impurity! found! in!





2009).! Large!aggregates!were! detected! in!Ctag6modified! LVs!eluted! in! the!





aggregates! using! AEX,! in! that! aggregates! possess! higher! number! of!
negatively!charged!molecules!i.e.!aggregates!bind!anion!exchange!resin!more!




nonspecific! force! and! has! been! shown! to! cause! the! formation! of!
macromolecular! complex! or! insoluble! aggregates! (Tabaka! et! al.,! 2014).!
Although! increase! in! protein! concentration! has! been! shown! to! be! directly!
related!to!the!occurrence!of!aggregates!(Treuheit!et!al.,!2002),!the!addition!of!
0.5%!BSA!to!biotin!rescued! infectivity!of!eluted!Ctag6LVs.! In! line!with! these!
results,! BSA! has! been! shown! to! mediate! a! significant! increase! in! protein!
catalytic!activity!by!crowding6promoter!stabilization!(Kuznetsova!et!al.,!2014).!
Moreover,!stabilization!of!viral!vectors!for!vaccine!for!examples!has!been!done!
through! formulation! and!addition! of! albumin!have!been! commonly! used! for!
vaccine!stabilization!(Brandau!et!al.,!2003).!Therefore,! it!could!be!proposed!




infectivity! observed.! This! stabilization! may! be! related! to! non6specific!








may! highlight! the! importance! of! media! formulation! as! X6vivoTM! contains! a!
mixture!of!proteins!and!sugars!which!may!have!impacted!vector!stabilization!
during! biotin6mediated! displacement! of! Ctag! from! streptavidin! resin.! This!
result! is!in!line!with!Carmo!et!al.,!(2008)!which!demonstrated!that,!unlike!γ-
RVs, LVs! increased! stability! required! the! addition! of! both! human! serum!
albumin! and! a! protein! solution! derived! from! bovine! serum.! These! results!





pockets.! This! competitive! elution! was! efficient! resulting! in! overall! yields! of!
≥60%,! using! biotin! supplemented! with! BSA.! It! is! interesting! to! note! that!
preliminary! elution! recoveries!with!decreasing! concentrations! of! biotin! from!
15mM!to!1.5nM!were!very!similar,!indicating!a!possible!avidity!effect!resulting!
in!small!differences!in!elution!recoveries,!in!the!presence!of!1006fold!increases!
in! biotin! concentration.!Although!biotin! has!~! 8! orders! of!magnitude!higher!
kinetics! than!Ctag,! the!simultaneous!binding!of!several!Ctag! to!streptavidin!
may!have! led! to! this!avidity!effectb! leading! to!a!synergistic!affinity!of!all! the!
interacting!bonds!formed!between!mimic!and!streptavidin.!Individually,!each!











is! unlikely! to! re6associate! as! biotin! should! immediately! block! streptavidin’s!
binding! sites.! With! that! in! mind,! it! may! be! postulated! that! the! incomplete!
recovery! of! total! Ctag6LV! titre! captured! by! streptavidin! may! be! due! to!
insufficient! incubation! times! of! elution! reaction.! Therefore,! longer! elution!
incubation!period!may!allow!for!the!displacement!of!all!Ctag!interactions!with!
streptavidin! by! biotin,! leading! to! complete! viral! recovery.! Accordingly,!
incubation!of!elution!at!higher!temperature!resulted!in!higher!yield!due!to!the!
higher! rate! of! displacement! reactions! occurring! at! room! temperature!
compared! to! 4°C.! Alternatively,! incomplete! elution! of! Ctag6LV! from!
streptavidin! beads! could! be! caused! by! non6specific! binding! of! vectors! to!
streptavidin!magnetic!beads.!This!in!turn!would!not!adhere!to!biotin6mediated!
competitive!elution!from!streptavidin,!resulting!in!incomplete!recovery!of!viral!
titres.! However,! non6specific! binding! of! Ctag6LV! to! streptavidin! magnetic!
beads!has!not!been!detected.!Control!unmodified!LVs!did!not!exhibit!any!non6
specific!binding!to!streptavidin!beads!either!by!non6specific!protein!interactions!





stalk! it! is! expressed! on.! However,! these! two! options! are! unlikely! to! have!









the! number! of!Ctag! interaction! per! viral! particle!would! have!allowed!better!








significant! capture! and! highest! overall! yield,! compared! to! lower! mimic!
expressions.!Moreover,!although!a!significant!difference!in!recoveries!between!
the!highest!and!lowest!Ctag!expression!was!observedb!the!difference!in!viral!
recoveries! were! not! statistically! significant.! This! could! have! been! further!
interpreted!if!Ctag’s!density!on!viral!particles!was!known.!First,!we!attempted!
to! estimating! its! density! by! quantifying! Ctag’s! expression! on! VPCs! by!
streptavidin!and!then!theoretically!proposed!a!density!on!viral!particles!based!





theoretical! assumption! proposed! 3! Ctag! molecules! expressed! per! viral!














selective!mechanism! in! vector! capturing,! it! could! be! postulated! that! eluted!
vectors!may!represent!higher!levels!of!purity!in!terms!of!product!and!process6
















of! both! infectious! titre! as!well! as! product! and!process6related! impurities! to!
guarantee!product!safety,!quality!and!efficacy.!The!high!degree!of!complexity!
of! viral! vectors,! in! terms! of! their! biology,! represents! a!major! challenge! for!








an! enzyme6linked! immunosorbent! assay! (ELISA).! Although,! this! assay! is!
simple,! fast!and!easy! to!run,! it!cannot!distinguish!between! intact,! infectious!
particles!and!free!proteins.!In!addition,!it!relies!on!calculating!particle!numbers!
based!on!a!conversion!equation!assuming!a!defined!number!of!proteins!per!





such! as! the! nanoparticle! tracking! analysis! (NTA)! using! Nanosight! or!




for! example! between! 107! and! 109! particle/mL! for! Nanosight! analysis.!
Moreover,! presence! of! background! particles! or! host! cell! debris! have! been!
shown! to! represent! limiting! factors! for! single! particle! analysis! as! these!are!
included!within!the!quantification!for!example!cell!derived!exosomes!(Mironov!
et! al.,! 2011).! Thus,! similarly! to! p24! measurement,! single! particle! tracking!






by! transduction! of! target! cells! for! the! measurement! of! marker! protein!
expression,!with!eGFP!being!the!most!commonly!used!(Geraerts!et!al.,!2006).!
The!use!of!this!method!allows!the!quantification!of!viral!particles!that!can!bind!
their! receptor! on! target! cells! and! induce! viral! entry! for! vector! genome!
integration! i.e.! transducing!particles.!However,! to! fully!elucidate! this!method!
its!biological!mechanics!need!to!be!examined.!In!order!to!infect,!viral!vectors!
must! first! travel! the!distance! to! target!adherent!cells,!which! is!governed!by!
their!diffusion!rates!in!culturing!solutions.!However,!the!efficiency!of!infectivity!
is! depicted! by! the! half6life! of! each! vectors.! For! example! the! half6life! at!
physiological!temperatures!is!between!6618!hours!for!different!strains!of!HIV6
1! (Layne! et! al.,! 1992).! Considering! that! the! depth! of! culturing!medium! of!
adherent!cells!is!usually!several!millimeters,!it!could!be!postulated!that!a!small!
portion!of!vectors!would!reach!target!cells!for!infectivity!during!its!half6life,!thus!










permissinvess! for! each! cell! type! towards! LVs.!This! concept! interestingly! is!
highlighted! by! the! observation! that! LVs! pseudotyped! with! measles! virus!
glycoproteins! were! able! to! efficiently! transduce! previously! LV6resistant!
quiescent! lymphocytes,! due! to! the! high! surface! expression! of! measles!
envelope’s!receptor!proteins!CD46!and!SLAM!(Frecha!et!al.,!2011).!Due!to!
these! varying! factors,! it! is! important! to! mention! that! comparison! between!




genome! in! the! viral! supernatant! or! integrated! proviral! DNA! copies! by!
quantitative!polymerase!chain!reaction!(qPCR).!This!method!when!applied!to!
the! viral! supernatant! however! leads! to! the!overestimation! of! viral! titre! as! it!
includes!non6infectious!particles! i.e.!bald!particles,! that!do!not!express!viral!
envelope,!as!well!as!free6floating!RNA!genome!in!vector!material.!Therefore,!
its!use!has!been! limited! to!high! throughput!screening!of!vector! titres!during!
producer!cell!line!development!for!example!(Ansorge!et!al.,!2010).!!
6.2.2% Quality%analysis%of%purified%LVs%%




process6related! impurities! are! contaminants!derived! from!vector! production!
such!as!host!cell!proteins!(HCP)!and!host!cell!nucleic!acids.!It!should!be!noted!
as!the!viral!envelope!of!virions!is!composed!of!the!host!cell!membrane,!host!




therapies! as! well! as! the! confidentiality! of! manufacturer! data,! insufficient!
information! on! vector! product! purity! is! available! in! the! public! domain.!
Nonetheless,! different! methods! are! used! to! evaluate! vector! quality! and!
measure!both!product6!and!process6related!impurities!present!in!viral!stocks.!!
A!useful! indicator!of!product!quality! is!a!derivative!calculation!based!on! the!
ratio!of!transducing!unit!to!total!physical!particles!(TU:PP),!termed!infectivity.!
Moreover,! determining! the! levels! of! cell6culture! process! impurities! are!
important!parameters!for!vector!purity.!Residual!levels!of!host!cell!protein!and!
DNA!(process6related)!or!plasmid!derived!DNA!(product6related)!are!routinely!
measured! in! final! vector! product! intended! for! clinical! use.! Nucleic! acid!
impurities! such! as! residual! packaging! plasmid! DNA! can! quantified! by!
quantitative!PCR!using!designed!primers!against!relevant!sequences!in!helper!
plasmids! (Sastry! et! al.,! 2004b! Yang! et! al.,! 2012).! Host! cell6derived! DNA!
impurities!can!be!detected!and!quantified!in!viral!product!by!using!a!fluorescent!
nucleic!acid!stain!such!as!PicoGreen®!(Bandeira!et!al.,!2012).!As!for!proteins,!
different!method! have! been!used! for! total! protein! analysis! of! LVs! such!as!
polyacrylamide! gel! electrophoresis! and! protein! staining! (Baekelandt! et! al.,!
2003).! Moreover,! specific! host! cell6derived! proteins! can! be! detected! and!









2007).!Accordingly,!due! to! the!potential! immunogenicity!of!HCP,! regulatory!
agencies! require! their! specific! quantification! in! final! gene! therapy! products!
(FDA!Guidance! for! Industry,! 1998).!Taking! these! factors! into! consideration!





processing! steps! for! any! vector! product! intended! for! human! applications.!
Therefore,!the!strength!of!a!downstream!processing!technique!lies!in!its!ability!
to!eliminate!vector!contaminants!while!maintaining!infectivity,!without!the!need!






















The! development! of! any! downstream! processing! strategy! for! viral! vectors!
should! allow! for! vector! concentration.! To! demonstrate! this! with! our!
methodology,!Ctag6LV! from!stock!was! subjected! to! capture! by! streptavidin!
Dynabeads,! followed! by! elution! in! 50X! volume! reduction! of! the! starting!
material,!using! 500µM!biotin!with! 0.5%!BSA! in!OptiMEM.!Concentration! of!
eluted!Ctag6LV!was!theoretically!possible!throughout!this!Chapter!due!to!the!
ease! in! manipulation! of! elution! volume! post6capture! by! magnetic! beads.!
Consistently,!almost!all!Ctag6LV!viral!particles!were!captured!on!streptavidin!
Dynabeads!with!increased!transduction!efficiencies!on!target!cells!resulting!in!











from! stock! was! subjected! to! streptavidin! Dynabeads! capture! followed! by! biotin6








parameter! to!consider.!High!purity! in! terms!of! removal!of!both!process!and!
product6related! impurities! is! a! prerequisite! for! overall! efficacy! of! purified!
vectors.!Since!our!developed!purification!selectively!captures!Ctag6LV! from!
surrounding!supernatant!and!recovery!from!matrix!is!selective!by!biotin!binding!












immature!particles,!which!are!not!capable!of! integrating! into! target!cells.! In!
order!to!quantify!viral!particles!only!(functional!or!not)!and!exclude!free!p24,!






eluted! vectors.! To! test! this,! neat! and! 50X! eluate! from! the! experiment!
performed!in!Figure!6.1,!were!thawed!and!subjected!to!both!infectivity!assay!
for! IU/mL! and! p24! ELISA! kit! for! PP/mL! (Figure! 6.2a6b).! Unlike! freshly!
determined! infectious! titre!of! 50X!eluate! sample,! one! round!of! freeze6thaw!
decreased!the!transducing!titre!by!almost!2!folds!with!4.29!±1.0!x105!IU/mL,!
which!was! still! higher! than! that! of! the! neat!sample! (6.59! ±0.6! x104!IU/mL).!
These! results! suggested! titre! loss! by! freeze6thawing! cycle! for!RDpro! to! be!
significant.! Nonetheless,! the! physical! particle! titre! was! quantified! by!









































Another! important! purity! parameter! to! determine! was! the! level! of! host6cell!
derived!DNA!contamination.!Given!the!specificity!of!our!vector!purification,!it!
could!be!anticipated!that!host6cell!derived!nucleic!acid!would!not!be!present!in!
our! eluate! vector,! as! DNA! does! not! exhibit! any! binding! to! streptavidin.!














(FT)! and! concentrated! eluate! 50X)! were! assayed! for! dsDNA! presence! by!
PicoGreen®.!(b)!Percentage!of!dsDNA!concentration!reduction!compared!to!starting!










kept! in! mind! however,! viral! particles! themselves! contain! host! cell6derived!
proteins!on!their!viral!surfaces.!Due!to!the!specificity!of!our!affinity!purification!
of! Ctag6LVs,! and! similarly! to! the! reduction! of! nucleic! acids,! it! could! be!
suggested!that!the!enrichment!of!Ctag6expressing!particles!would!be!greater,!
which! in! turn! leads! to! lower!amounts!of!HCP.!To! test! this,!purified!Ctag6LV!
samples!from!Figure!6.2!were!compared!to!starting!vector!supernatant!by!first!
evaluating!their!protein!content!by!silver!stain!analysis!(Figure!6.4).!Culturing!
medium! (plain! DMEM)! and! elution! buffer! OptiMEM,! with! elution! excipients!









65kDa! in! the! eluate! sample! at! 1:100,! seemed! to! represent! BSA! which! is!

















6.5a).! A! control! consisting! of! cellular! supernatant! from! NT6293T! cells! was!
included! along! the! starting! and! purified! viral! vectors! of! Figure! 6.2.! The!
transfection!of!cells!to!produce!transient!LVs!resulted!in!an!increase!in!host!
derived!proteins!detected! in!viral!supernatant!with!1856!±56!ng/mL!of!HCP!
compared! to! 1139! ±274!ng/mL! of! HCP! quantified! in! non6transfected! 293T!
cells.! This! increase! could! have! resulted! from! the! HCP! detected! on! viral!
particles!but!more!likely,!represents!the!cellular!debris!due!to!the!transfection!
and! viral! production! of! HEK293T! cells.! In! this! first! experiment,! in! order! to!
quantify!HCP,!samples!were!diluted! to! fit!within! the!standard!curve.!Protein!
quantification!of!purified!Ctag6LV!from!our!purification!resulted!in!undetectable!
amounts!of!protein!(<100ng/mL)!at!the!highest!dilution!of!25X.!Therefore,!the!











(NT),! starting! viral! supernatant! (neat)! and!purified!Ctag6LV! (eluate!50X).!Samples!
were! diluted! 25X,! 50X! and! 100X! for! assay! using! sample! diluent! buffer.! (b)!














Our! developed! purification! could! be! regarded! as! superior! to! currently!
employed!schemes!due!to!its!efficiency!in!both!product6!and!process6related!
impurities! clearance! in! a! one6step! capture! process.! All! current! purification!
schemes! employed! in! viral! downstream! processing! have! a! common! DNA!
















Our! developed! purification! therefore! offers! a! substantially! improved!
purification!process!compared!to!the!currently!used!purification!schemes!for!











In! previous! Chapters,! we! have! demonstrated! successful! purification! by!
compete! capture! of! Ctag6LV! by! streptavidin! matrix! and! their! subsequent!
competitive! elution! by! biotin.! We! have! also! established! superior! levels! of!
vector!product!purity!from!our!developed!method.!However,!for!its!potential!as!





gene! therapy! vector! production.! In! biopharmaceutical! manufacturing,!
downstream!processing!is!estimated!to!account!for!75680%!of!its!operational!









vectors! productions.! Its! potential! quickly! recognized! due! to! its! ease! in!
scalability,! fast! processing! times,! consistency! and! automation.! As! a! result,!




purification! of! LVs! by! exploiting! either! LV! charge! (anion! exchange!
chromatography,!AEX)!and/or!size!(size!exclusion!chromatography).!!
The! large6scale! processing! of! clinical! grade! LVs! which! was! discussed! in!
Section! 1.3.4.2,! combines! several! methods! within! multi6step! processing!
schemes.! A! summary! of! these! clinical6grade! purification! ‘trains’! from! the!
different!institutions!are!depicted!in!Figure!1.7.%As!expected,!chromatography6



























between! 106100nm! (Jungbauer! and! Hahn,! 2008)! and! up! to! 400nm!
(Morenweiser,! 2005).! It! should! be! mentioned! that! the! majority! of!
chromatography! resins! currently! available! for! viral! purification! have! been!
initially! optimized! for! protein!purification,!which! explains! the! relatively! small!
pore! sizes.! Consequently,! viruses! that! can! enter! larger! pores! have! been!
shown!to!diffuse!into!the!intra6particle!channels!261006fold!slower!than!proteins!
(Ljunglöf!et!al.,!1999).!Therefore,!given!that!the!mass!transfer!within!a!particle6
based! column! is! limited! to!diffusion,! this! type!of! stationary! phase! can!only!
accommodate!for!low!flow!rates!to!allow!enough!time!for!viral!vectors!to!diffuse!
in!and!out!of!the!pores.!Additionally,! it!has!also!been!demonstrated!that!the!




suggested! the! need! for! larger! pore! size! to! accommodate! viral! vector!




protein! bound! to! a! chromatography!matrix! at! certain! conditions! in! terms!of!
solvent!and!protein!concentration.!Therefore,! the! lower! this!protein!capacity!
parameter,! the! less! efficient! a! chromatographic! medium! is! at! target!
purification.!!
The! development! of! monolith6based! chromatography! offered! several!
advantages!compared!to!porous6particles!and!their!value!has!been!recognized!
for!several!downstream!processing!of!viral!vectors.!Monolithic!adsorbent!is!a!
single! continuous! porous! polymeric! surface! with! connected! channels! that!






























dynamic! binding! capacity! than! membranes,! as! well! as! allowing! more!
controllable! flow! distribution! compared! to! hollow! fiber! and! radial6flow!
membrane! adsorbers! (Gagnon,! 2008).! Moreover,! the! formation! of! eddy!
currents,! which! is! the! swirling! and! reverse! current! of! a! fluid,! have! been!
demonstrated!for!most!chromatographic!matrices!except!for!monoliths!(Wolf!
and!Reichl,!2011).!Given!the!labile!structure!of!viral!particles,!this!phenomenon!
in! fluid! dynamic! should! be! considered! for! viral! vector! purification! as! eddy!
formation!can!cause!viral!particle!damages!resulting!in!lower!infectious!vector!
elution! from! chromatographic! columns.! Therefore,! monolith6based!















are! currently! employed! for! the! separation! of! LV! particles.! Anion! exchange!
chromatography! applications! are! widely! used! for! VSV6g! pseudotyped! LV!
purification!for!both!clinical!and!research!applications!(Slepushkin!et!al.,!2003b!
Rodrigues! et! al.,! 2007b! Schweizer! and!Merten,! 2010b! Lesch! et! al.,! 2011).!
However,!since!this!process!exploits!charge6charge!interactions!between!viral!
surface!and!matrix6immobilized!anions,!it!suffers!from!low!specificity!resulting!
low! viral! target! dynamic! binding! capacity! due! to! background! absorption! of!
impurities! that!affect! the!quality!of! the!purified!product.!This!method!of!LVs!
purification!also!often!results!in!co6elution!of!negatively!charge!contaminates!
such! as! nucleic! acid! as! its! elution! is! non6specific.! This! in! turn! requires!
additional! techniques! for! vector! polishing.! Therefore,! in! the! absence! of! a!
suitable!specific!affinity6based!chromatographic!purification!method!that!offers!











to! the! type! of!modification,! as!well! as! the! usage! of! the! non6specific! biotin!
receptor! avidin,! a! streptavidin! specific! biotin! mimic! may! offer! superior!
resolution! in! terms! of! target! purification! and! product! purity.! Therefore,! the!







using! biotin,! resulting! in! recoveries! ≥! 60%.! As! an! affinity! purification! of!
infectious!viruses,!the!interaction!between!Ctag!and!streptavidin!provides!high!






•! Demonstrating! the! application! of! our! purification! as! an! affinity!


















prior! Dynabeads! optimization! (Section! ! 4.8),! based! on! their! surface! areas!
(Table! 7.1).! In! preliminary! capture! experiments! in! Chapter! 4,! 50µL! of!
Dynabeads!was!used! to! capture! all! infectious!Ctag6LVs.!To! determine! the!
amount!of!SVP!beads!required!for!a!comparison,!the!equivalent!of!100µL!of!
Dynabeads! surface!area! (9.92! x107! µm2)! for!SVP!particles!was!used.!The!
number!of!beads!was!determined!by!calculating! the!SA!of!both!Dynabeads!
























were! collected! and! their! virus! titres! were! determined! by! infectivity! assay!
(Figure!7.1a).!SVP!particles!did!not!seem!to!bind!any!Ctag6LVs,!as!indicated!
by! the! presence!of! the! complete!Ctag6LV! titre! in! the! flow6through! fractionb!
resulting!in!no!statistical!difference!compared!to!its!neat!fraction.!To!determine!
whether! streptavidin! conjugated! on! SVP! particles! are! functional,! both!















particles.% (a)%NM6!and!Ctag6LVs! from!stock!were! incubated!with!Spherotech!SVP!
streptavidin!coated!100µm!particles!for!2!hours!at!4°C!with!gentle!rotation.!Loading!
of!mixture!onto!40µm!cell!strainers!isolated!SVP!particles!from!flow6through!fractions.!
Viral! titres! for!all! collected! fractions!were!determined!by! infectivity!and!values!are!
presented!±!standard!deviation!(SD)!of!triplicate!determinations!with!ns!p!≥!0.05.!(b)%
Histograms! of% streptavidin! magnetic! Dynabeads% and! Spherotech! SVP! particles!




















PBS!and!a! fraction!was! collected! for! viral! assessment!without! any! volume!


















bead! fraction! resulted! in! a! 996fold! increase! in! viral! titre! (9.54! x106! IU/mL)!
compared! to! starting!material.! This! result! further! highlights! the! increase! in!







even! though! this! value! may! be! overestimated! given! the! bead6dependent!
increase!in!infectivity.!Nonetheless,!in!this!experiment!we!have!demonstrated!








Figure% 7.2:% Scalable% purification% and% concentration% of% Ctag=LV% using%
streptavidin%magnetic%beads.%(a)%NM6!and!Ctag6LVs!from!stock!were!subjected!to!
the!developed!purification!process!with!magnetic!Dynabeads.!Post6capture!of!viral!
vectors,! elution! reaction! occurred! in! 100X! volume! reduction! for! concentration! of!





The! use! of! Dynabeads! for! large! vector! volume! processing! is! not! an!
economically!feasible!option.!An!alternative!platform!that!can!be!easily!scaled!
up!with!good!economics!is!thus!required!for!the!wide6spread!applicability!of!
our! method.! Correspondingly,! streptavidin6based! affinity! chromatographic!
purification!of!viruses! is!an!attractive!option.!Monoliths6based!columns!offer!
several!advantages!compared!bead6packed!or!membrane6based!columns.!In!
a! collaboration! with! BIA! separation,! we! aimed! at! testing! their! CIMacTM!
streptavidin! 0.1mL! analytical! columns! for! the! purification! and! subsequent!
biotin6mediated!elution!of!captured!Ctag6LVs.!CIMacTM!analytical!columns!are!
high6performance!monolithic!columns!which!have!a!bed!volume!of!100µL!and!










the!manufacturer’s! recommendation,! the! column! was! placed! in! an! upright!
position! and! connected! to! a! peristaltic! pump! using! connector! tubes! as!




was! then!washed!with! 50! column! volume! (CV)! of! PBS!with! a! flow! rate! of!
1.5mL/min.!Subsequently,!the!column!was!primed!with!50!CV!of!plain!DMEM,!
which! represent! the! vector6containing!media! of! viral! supernatants.! Then! to!
determine! the! non6specific! binding! of! the! CIMacTM! streptavidin! analytical!
column,!5mL!of!NM6LV!was!loaded!with!a!flow!rate!of!2mL/min,!and!its!flow6
through!was!collected.!After!having!washed!the!column!with!50mL!of!PBS,!









to!PBS,! two! fractions! of! 1.5mL,! termed!E1!and!E2,!were! collected!as! they!













column! resulted! in! significant! vector! binding! to! immobilized! streptavidin,! as!
indicated!by!the!presence!of!9.11!x!104!total!TU!detected!in!all!of!the!five!10mL!
collected! flow6through! fractions,! which! represented! a! total! yield! of! 4%! of!
transducing!units!(Figure!7.3d6e).!The!low!starting!viral!titre!was!likely!due!to!
the! use! of! non6optimized! conditions! of! serum6free! freeze6thawed! viral!
supernatant.!Moreover,!the!washing!of!the!column!did!not!displace!any!bound!
LVs! indicating! specific! and! high! binding! affinity! of! Ctag6LV! to! the! column.!
Furthermore,!captured!vector!was!eluted!and!six!fractions!(E1!to!E6)!of!1.5mL!
total! volume! each! were! collected! followed! by! a! 7.5mL! E7! fraction.! Upon!
loading!of!the!elution!buffer,!the!first!collected!fraction!E1!contained!1.01!±0.09!
x104! IU/mL!of!Ctag6LV,!which! represents! 22! ±1.5%!of! input! viral! titre.! The!








achieved! in! all! elution! fractions! by! biotin6displacement! of! Ctag6LV! in! this!
preliminary! affinity! chromatography! run! (Figure! 7.3e).! Therefore,! this!
experiment!provided!the!feasibility!of!our!developed!methodology!application!







Figure% 7.3:% Affinity% chromatography% purification% of% Ctag=LV% using% CIMacTM%
streptavidin%analytical% column.% (a)% Image! illustrating! chromatographic! run! using!
peristaltic!pump!with!a!white!arrow!pointing!to!the!CIMacTM!column.%(b)%Diagram!of!









In! this! Chapter,! we! have! demonstrated! the! feasibility! of! scaling! up! our!
developed! one6step! purification! process! which! is! based! on! the! specific!
interaction!between!Ctag!and!streptavidin.!This!has!been!established!by!the!





















the! lack! of! NM6LVs! binding.! Surprisingly,! the! analytical! CIMacTM! monolith!
column!captured!a! total!of!2.26!x!106! transducing!Ctag6LV!units!during! the!




magnetic! beads,! which! only! attained! partial! capture! with! incubations! ≤30!
minutes! (Section!4.8).!Moreover,!Ctag’s! interaction!with! streptavidin! on! the!
column! seemed! stable! during! column! washing,! highlighting! their! strong!
binding!kinetics.!Unlike! the!non6specific!heparin!affinity!chromatography! for!
LVs! purification! (Segura! et! al.,! 2007,! 2008),! streptavidin! affinity!










during! the! chromatographic! purification! of! Ctag6LV.! Furthermore,! the!
desorption!of!captured!vectors!from!the!matrix!was!achieved!by!the!loading!of!
the! elution! buffer! formulated! in! X6vivoTM! containing! 15mM! biotin! and! 0.5%!
BSAb! resulting! in! an!overall! yield! of! 20%!with! a! 26fold! concentration! at! the!
second!elution!peak.!Interestingly,!matrix6bound!LVs!continued!to!desorb!from!
the!column!even!after!the!loading!of!150CV!elution!buffer,!indicating!that!the!












of! hexahistidine! (His6)6tagged! viral! vectors! using! IMAC,! either! by! random!
incorporation!of!host6cell!derived!His6!protein!(Cheeks!et!al.,!2009)!or!using!
randomly! inserted! His6! into! engineered! VSV6g! variants! (Yu! and! Schaffer,!
2006)b! requires! high! concentration! of! imidazole! for! column! desorption.!
Although!reported!elution!efficiencies!were!high!(69%),!inactivation!of!LVs!was!
demonstrated!and!was!attributed!to!high!imidazole!concentrations!(Ye!et!al.,!
2004b! Cheeks! et! al.,! 2009b! Segura! et! al.,! 2013).! Therefore,! affinity!
chromatographic!processes!relying!on!either!heparin!binding!or!incorporation!
of!His6!necessitate!harsh!desorption!conditions,!which!are!also!often!observed!
for! AEX,! impacting! the! infectivity! of! labile! LVs.! Our! developed! purification!
relying!on!the!competitive!elution!of!captured!Ctag6LV!by!biotin,!allowing!the!
gentle! column!desorption! of! bound! vectors.!As! discussed! in!Section! 4.2.3,!
Chen! et! al.,! (2010)! demonstrated! the! desthiobiotinylation! of! LVs! and! their!






Comparatively,! our! streptavidin6based!monolith! chromatography! resulted! in!
complete! capture! of! all! infectious! titre,! all! the!while! resulting! in! incomplete!
desorption!from!the!column!using!15mM!biotin!within!approximately!7!minutes.!




Nonetheless,! the! preliminary! recovery! of! 20%! was! encouraging! since! the!




and! feasibility! of! our! method! as! an! affinity! purification! for! scalable! LVs!
purification.! In!collaboration!with!Dr.!Glenda!Dickson!and!Dr.!David!Darling!
from! Prof.! Farzin! Farzaneh’s! laboratory! at! King’s! College! London,! the! 4/5!
remaining! streptavidin! analytical! columns! will! be! tested! for! the! affinity!
chromatographic! purification! of! Ctag6LV.! Given! the! multi6process! of! most!
clinical6grade! downstream! processing! of! LVs,! the! use! of! our! developed!
modified!vector!isolation!effectively!reduces!the!number!of!processes!required!
for!high!purity!vector!product.!This!in!turn!would!decrease!the!cost!of!vector!












a! major! bottleneck! for! their! advancement! in! both! pre6clinical! and! clinical!
applications.!The!inefficiency!of!each!of!these!methods!is!emphasised!by!the!
requirement! of! purification! schemes,! which! consist! of! at! least! 4! different!
technologies!(Merten!et!al.,!2016).!These!methods!aim!to!either!debulk! the!
surrounding!supernatant!from!viral!vectors!(e.g.!UF/DF!and!SEC)!or!rely!on!
overall! charge! of! viral! particles! for! purification! (e.g.! AEX).! Although! AEX!
suffers!from!low!specificity!and!co6elution!of!negatively!charge!impurities,!it!is!
currently! the!most!widely!applied!purification! technology! for!both! laboratory!
and!clinical!scale!LV!purification,!with!several!commercial!kits!available!such!
as! Merck! Millipore’s! Fast6Trap! kitb! ABM’s! PuRetro®! LV! kitb! Cellbiolabs’s!
ViraBind!LV! kit! and! finally!Sartorius’s!Vivapure! LentiSELECT!kit.!However,!
desorption! from!AEX!matrices!requires! the!use!of!harsh! reagents!and! thus!
efficient! elution! comes! at! the! cost! of! the! most! important! objective! of! any!
downstream!process!which!is!to!maintain!vector!infectivity.!Thus,!all!of!these!
limitations!and!the!constraint! in!utilizing!at! least!4! technologies! in! the!multi6
step!schemes,!are!in!turn!translated!into!the!presently!acceptable!overall!yield!
of! 30%! for! clinical! downstream! processing! of! LVs,! with! published! yields!
ranging!between!20640%!(Merten!et!al.,!2011).!!





desorption! from! affinity! ligands.! These! two! features! are! key! in! any! viral!
purification!method!for!its!efficacy!in!vector!manufacturing,!both!technically!and!
economically.! Lectin6based! affinity! ligands! suffer! from! non6specific! vector!















their! subsequent! purification! using! monomeric! avidin! followed! by! biotin6
mediated!desorption!from!column!(Chen!et!al.,!2010).!However,!this!strategy!
had! several! limitations! due! to! the! relative! complexity! of! viral! engineeringb!
involving! co6expression! of! three! exogenous! proteins! in! packaging! cells.!
Moreover,!the!synthesis!of!desthiobiotin!in!these!cells!requires!the!addition!of!
76DAPA! into! the! culture,! which!may! contain! traces! of! biotin! rendering! this!
strategy!ineffective!for!complete!viral!capture.!In!our!strategy,!a!cell!surface!
expressing! synthetic! biotin! mimicking! peptide,! Ctag! was! genetically!
engineered! into! packaging! cells,! thus! effectively! relieving! the! need! of! any!
exogenous! protein! expression! other! than! the! peptide! itself.! Strikingly,! its!
passive! incorporation!onto! the!surface!of!viral!particles!upon!virion!budding!
was! both! necessary! and! sufficient! for! complete! vector! capture! from! viral!
supernatant!in!a!one6step!process.!The!simplicity!and!specificity!of!this!affinity6
based!isolation!was!shown!to!be!independent!of!viral!envelope!glycoproteins.!
The! indirect! nature! of! Ctag! modification! on! viral! particles! effectively!
demonstrates!that!our!developed!purification!may!represent!a!universal!viral!
vector! isolation! technique.!As! it! is! independent!of!vector!genetic!material,! it!
could!be!applied!to!any!strain!of!viral!vectorsb!both!enveloped!viruses,!without!
the! requirement! of! envelope! glycoprotein! engineering,! and! non6enveloped!






and! applied! onto! stable! producer! cell! lines! by! their! genetic! engineering! to!
express!Ctag!proteins.!To! the!best!of!our!knowledge,! this! report! represents!
the!first!use!of!a!synthetic!biotin!mimicking!peptide!for!the!purification!of!viral!
vectors.! Moreover,! the! elegance! and! novelty! in! our! desorption! strategy! is!
based!on!the!competitive!binding!of!biotin!to!streptavidin,!thus!displacing!the!
bound!mimic!causing!the!release!of!LVs.!This!type!of!elution!was!carried!out!











eluted! LVs! in! terms! of! both! product6! and! process6related! impurities.! The!
selective!capture!of!Ctag6expressing!viral!particles!followed!by!their!elution!in!
a! biotin6dependent! manner! resulted! in! a! minimum! of! 36logs! and! 26logs!













manufacturing! of! LVs.! The! reduction! of! current! schemes,! after! vector!
clarification,!to!potentially!one!affinity6based!chromatographic!purification!step,!









In! this! project,! a! cyclical! streptavidin! binding! peptide! Ctag,! derived! from! a!
phage!display!screening!by!Giebel!et!al.,!(1995),!was!established!as!an!affinity!


















peptides! to! determine! their! universal! mimicry,! in! which! most! have! failed!
(Dudak!et!al.,!2011).!Further! investigation! into! the!molecular! interactions!of!
HPQ! to! streptavidin! could! elucidate! its! full! interplay,! which! in! turn! would!
highlight!key! features! that!are!responsible! for!streptavidin!or!avidin!specific!
binding! of!mimics.!Moreover,! as!Ctag! demonstrated! increased! streptavidin!
binding! compared! to! commercially! used! linear! peptides! of! the! Strep6Tag®!
system,! investigating! the! binding! kinetics! of! these! two! structurally! different!
peptides!would!be!interesting!to!further!understand!the!superiority!of!cyclical!
peptides! compared! to! linear! ones.! And! finally,! since! Ctag! with! its! flanked!
cysteine! residues! (ECHPQGPPCIEGRK)! demonstrated! increased!
streptavidin! binding! compared! to! un6flanked! cysteine! residues! of! sCtag!
(CHPQGPPC)b!the!effect!of!these!flanking!residues!on!cyclical!peptides!should!
be!determined!as!it!would!be!interesting!to!assess!whether!they!alter!binding!






along! with! viral! envelope! glycoprotein.! This! simple! principle! of! protein!




been! established! in! the! scientific! literature! for! endowing! vectors! with! new!
functions! such! as! purification! (Chen! et! al.,! 2010)! or! immune! response!




enhanced! immune! reactions! against! Ctag!modified! vectors! should! then! be!
evaluated!in%vivo,!which!would!not!be!required!for!ex%vivo!applications.!Unlike!
AAV!and!AdV,!LVs!elicit!very!low!immune!responses!which!mainly!targets!the!
vector! transgene! rather! than! viral! specific! antigens! (Bessis! et! al.,! 2004b!
Follenzi! et! al.,! 2007).! Although,! the! intravenous! administration! of! LVs! into!
immunodeficient!mice!resulted!in!no!apparent!sign!of!toxicity!with!stable!gene!
expression!(Pfeifer!et!al.,!2001b!Follenzi!et!al.,!2002b!VandenDriessche!et!al.,!
2002)b! administration! of! vectors! carrying! CMV6driven! transgenes! into!
immunocompetent! mice! resulted! in! immune! responses! against! transgenes!
leading!to!clearance!of!transduced!cells!(Follenzi!et!al.,!2004b!Annoni!et!al.,!
2007).!Thus,! the! investigation!of!Ctag6mediated! immune!response!could!be!
evaluated!by!the!systemic!administration!in!immunocompetent!C57BL/6!mice!
with! both! NM6LV! and! Ctag6LV,! separately.! The! potential! Ctag6mediated!
induction! of! humoral! immune! response! can! then! be! analysed! a! couple! of!
weeks!after!injection!by!the!detection!of!anti6Ctag!antibodies.!Additionally,!the!
adoptive! transfer! of! splenocytes! can! be! used! to! assess! Ctag6mediated!
immune!reaction,!in!which!spleens!of!treated!mice!could!be!harvested!and!co6
culture! in% vitro! with! mice6derived! cell! lines,! such! as! BW5,! transduced! to!
express! Ctag.! If! Ctag6LV! induced! an! immune! response! in% vivo,! then!
accordingly! the!co6culture!of!Ctag6LV! injected!mice’s!splenocytes!with!mice!
cell! lines! expressing! Ctag! would! result! in! effector! functions! that! can! be!
detected! such! as! IFNγ! production! for! example.! Given! its! relative! size! and!
possible! low! density! per! virion,! it!may! be! unlikely! for! Ctag6modified! LV! to!
induce! an! immune! response! greater! than! that! observed! for! control! non6
modified!vectors.!Since!Ctag!exhibited!superior!streptavidin!binding,!as!well!
as!efficient!displacement!by!biotin!out6competition,! it!may!be!proposed! that!













and! troubleshooting! of! its! elution! in! terms! of! overall! vector! avidity! for!
streptavidin.!SEM!analysis!of!modified!vectors!was!performed!on!negatively!
stained! samples!with! streptavidin! conjugated! to! colloidal6gold! particles! and!
resulted!in!unsuccessful!peptide!quantification!due!to!significant!non6specific!
background! staining.! Future!efforts! for!Ctag!quantification! on! viral!particles!
could!be!achieved!by!staining!immobilized!modified!vectors!with!streptavidin!
conjugated! to! a! quantum! dot! (Qdot).! The! recently! developed! Qdot! are!
fluorescent! semiconductor! nanocrystals! composed! of! a! cadmium! selenide!
core!which!can!overcome!spectral!limitations!of!organic!fluorophores!such!as!




2012).! The! quantification! of! proteins! on! the! surface! of! viral! vectors! is!





of! membranes! and! vesicles! and! thus! could! be! used! in! conjunction! to!
streptavidin! gold6labeling! for! Ctag! quantification! per! virion.! Finally,! an!








envelope! glycoproteins! along! with! Ctag! on! modified! vectors! would! be!







was! sufficient! for! the! recovery! of! ≥! 60%! of! streptavidin6captured! Ctag6LV.!
Biotin6mediated! elution! of! infectious! particles! was! demonstrated!
simultaneously!with!a!buffer!exchange!step! into! three!commonly!used!viral!
cultivation!medium!(X6vivoTM615,!OptiMEM!and!DMEM).!However! functional!
vector! recovery! required! the! addition! of! excipients! such! as! BSA! to! biotin6
containing!solutions.!The!supplementation!of!protein!additives! for! increased!
infectious! vector! recovery! is! in! line! with! Carmo! et! al.,! (2008)! which!
demonstrated! the! necessity! of! both! human! serum! albumin! and! a! protein!




infancy! of! LV! bioprocessing! and! their! use! in! both! pre6clinical! and! clinical!
applications.!With! their!clinical!and!potential!commercial!progression,! future!
efforts! into! optimal! LV! formulation! is! highly! desirable.! The! use! of! animal6
derived!excipients!however!is!not!appropriate!from!a!regulatory!point!of!view.!
Thus!other!excipients!would!have!to!be!used!for!therapeutic!application!of!LVs!











purification!holds!very!promising!potential! in! terms!of!high!overall! yield!and!
product! purity,! its! translation! for! both! pre6clinical! and! clinical! applications!
require!the!use!of!alternative!streptavidin!conjugated!platforms!that!allow!the!






(King’s! College! London)! for! the! translation! of! our! method! into! affinity!
chromatographic!purification!of!large6scale!LV!volumes.!Future!work!will!aim!
to!compare!and!contrast!the!efficiency!of!adsorption!of!the!different!columns!





of! purified! vectors.!Moreover,! an! additional!collaboration!with!Spheritech! is!
currently!on6going!as!well! for! the! translation!of!our!method! into! large6scale!
vector! downstream! processing.! With! Spheritech’s! innovation! in! polymer!
design!and!manufacturing,!chromatographic!column!molded!with!monomeric!
streptavidin!immobilized!on!biodegradable!polymers!will!be!tested!for!Ctag6LV!
purification.! Interestingly,! the! use! of! monomeric! streptavidin! may! be!
advantageous! compared! to! tetrameric! streptavidin! due! to! its! monovalency!













virus! purification!which! resulted! in! up! to! 4! times!higher! overall! productivity!
compared!to!batch!mode!chromatography!(Kröber!et!al.,!2013).!Relevantly,!
Pall! Life! Sciences! have! recently! developed! the! first! disposable! simulated!
moving!bed! chromatography!platform! for! continuous! compound!purification!




or! stably! from! packaging! cells,! may! be! processed! in! a! fully6automated!
operation! unit! which! allows! for! microfiltration! followed! by! a! continuous!
chromatographic! streptavidin6based! column! for! affinity! purification.! Such! a!
specific!and!efficient!downstream!processing!of!LVs!could!effectively!replace!
the! current! multi6step! technologies! employed! for! large6scale! vector!
bioprocessing!for!both!research!and!clinical!applications.!With!their!increasing!
demand! in! both! pre6clinical! and! clinical! studies,! this! in! turn! would! aid! the!





purifications,! which! can! also! be! applied! to! different! vectors! based! on!






in! the!production!of! genetically!engineered!CAR6T! cells! for! immunotherapy!




cells! still! remain! refractory! to! lentiviral! transduction! despite! several!
improvements!(Follenzi!et!al.,!2000b!Salmon!et!al.,!2000).! In!particular,! this!
includes!early!progenitor!hematopoietic!stem!cells!in!G0!(Sutton!et!al.,!1999)!
and! resting!T! lymphocytes! ! (Dardalhon!et!al.,!2001).!However,! it!has!been!
shown! that! inducing! resting! T! cells! to! enter! the! G1b! cell! cycle! phase! by!
stimulation! through! the! T6cell! receptor! (signal! 1)! and! CD28! co6stimulation!




against! both! CD3! and! CD28.! Commercially! available! products! for! these!
antibodies!are!either!in!a!soluble!format!(Miltenyi!Biotec),!covalently!coupled!
to! magnetic! beads! (Dynabeads®! Human! T6Activator! CD3/CD28,!
Thermofisher! Scientific)! or! conjugated! to! polymeric! nanomatrix! (TransAct!
CD3/CD28!kit,!Miltenyi!Biotec),!all!of!which!are!very!expensive.!The!preferred!
method!of!activation! is! achieved!by! using!Dynabeads®!Human!T6Activator!
CD3/CD28! which! has! been! shown! to! induce! superior! stimulation! of! cells!
compared!to!soluble!mAbs!(Levine!and!June,!2013).!Since!these!beads!are!
under!restricted!license!and!require!an!extra!step!for!their!removal!in!CAR!T!
cell! manufacturing,! it! is! desirable! to! induce! T! cell! stimulation! followed! by!
transduction!in!a!simplified!manner.!!
It!was!proposed!that!if!single!chain!variable!fragments!(scFvs)!of!anti6CD3!and!
anti6CD28! mAbs! are! expressed! on! LV! surfaces,! then! both! activation! and!
transduction!of!T!cells!would!occur!in!a!one6step!process.!There!is!however!a!
precedent! for! the! expression! of! aCD3! scFv! on! LVs,! whereby! the! MLV!





induced! their! activation,! infectivity! was! very! poor! due! to! deficient! fusion!
activity.!To!overcome!this!limitation!and!rescue!infectivity,!chimeric!envelopes!
were!co6expressed!with!wild6type!VSV6g.!The!process!of!viral!particle!painting!
relieves! this! problem! as! membrane! bound! scFv! of! aCD3! and! aCD28!
expressed! on! CD8α! stalks! would! get! passively! incorporated! onto! viral!
particles,! in! a! similar! manner! as! Ctag.! This! method! may! offer! several!
advantages!over!the!current!protocol!used!for!ex%vivo%T!cell!expansion!and!
activation!for!LV!transduction!by!eliminating!the!need!to!purchase!expensive!
reagents!and! reducing! time! in!culture! for!adoptive!T!cell! therapy!protocols.!
Moreover,!this!process!may!also!enable!the!modulation!of!lymphocyte!signals!
as! desired.!Since! the! expression!of! scFvs!on! viral! particles! is! achieved!by!
retroviral! transduction! of! LV! producer! cells,! regulating! the! transduction!
efficiencies!of!these!cells!can!therefore!modify!the!type!of!molecules!and!their!
plasma!membrane!densities.!Optimal!T!cell!stimulations!can!then!be!reached!













































Fc! spacer! were! produced! from! both! NM6! and! Ctag6293T! cells.! Both! virus!
supernatants!(NM6LV!and!Ctag6LV)!were!then!used!to!transduce!T6cell!derived!from!
a! healthy! donor! using! retronectin6coated! plates.! Post6retronectin! recovery,! non6
transduced!and!transduced!T!cells!were!harvested!and!stained!with!an!anti6human6
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